



## Clinical trial results:

### A Phase II, Randomized Study of Atezolizumab (AntiPD-L1 Antibody) Administered as Monotherapy or in Combination with Bevacizumab Versus Sunitinib in Patients with Untreated Advanced Renal Cell Carcinoma

#### Summary

EudraCT number	2013-003167-58
Trial protocol	CZ DE IT GB ES FR RO PL
Global end of trial date	08 January 2019

#### Results information

Result version number	v2 (current)
This version publication date	18 December 2019
First version publication date	29 October 2017
Version creation reason	

#### Trial information

##### Trial identification

Sponsor protocol code	WO29074
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01984242
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	Roche Trial Information Hotline, F. Hoffmann-La Roche AG, +41 61 6878333, global.trial_information@roche.com
Scientific contact	Roche Trial Information Hotline, F. Hoffmann-La Roche AG, +41 61 6878333, global.trial_information@roche.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 January 2019
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	08 January 2019
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To estimate the efficacy of atezolizumab and bevacizumab combination and atezolizumab monotherapy compared with sunitinib as measured by progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) via an independent central radiologic review in the intent-to-treat (ITT) population and in participants who had detectable levels of programmed death–ligand 1 (PD-L1) expression on tumor-infiltrating immune cells (immunohistochemistry [IHC] IC1/2/3)

Protection of trial subjects:

This study was conducted in full conformance with the International Council for Harmonisation (ICH) E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki, or the laws and regulations of the country in which the research was conducted, whichever afforded the greater protection to the individual. The study protocol, Informed Consent Forms (ICFs), any information to be given to the participants, and relevant supporting information were submitted to the Institutional Review Boards (IRBs)/Ethics Committees (ECs) by the Principal Investigators and reviewed and approved by the IRB/EC before the study was initiated. In addition, any participant recruitment materials were also approved by the IRB/EC.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	08 January 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Czech Republic: 1
Country: Number of subjects enrolled	Spain: 8
Country: Number of subjects enrolled	France: 11
Country: Number of subjects enrolled	United Kingdom: 31
Country: Number of subjects enrolled	Germany: 3
Country: Number of subjects enrolled	Italy: 5
Country: Number of subjects enrolled	Poland: 6
Country: Number of subjects enrolled	Romania: 4
Country: Number of subjects enrolled	United States: 236
Worldwide total number of subjects	305
EEA total number of subjects	69

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	192
From 65 to 84 years	109
85 years and over	4

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Total 305 participants were enrolled in this study. Participants enrolled in atezolizumab (except European Union [EU] participants) or sunitinib group could crossover to receive atezolizumab and bevacizumab combination therapy in case of disease progression.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Atezolizumab and Bevacizumab

Arm description:

Atezolizumab 1200 milligrams (mg) and bevacizumab 15 milligrams per kilogram (mg/kg) were administered as intravenous (IV) infusions every 3 weeks (q3w) on Day 1 and Day 22 of each 6-week cycle until disease progression.

Arm type	Experimental
Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	RO5541267
Other name	Tecentriq
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

1200 mg IV q3w

Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	Avastin
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

15 mg/kg IV q3w

<b>Arm title</b>	Atezolizumab
------------------	--------------

Arm description:

Atezolizumab 1200 mg was administered as IV infusion q3w on Day 1 and Day 22 of each 6-week cycle until disease progression. Upon disease progression, participants (except EU participants) could crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.

Arm type	Experimental
Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	RO5541267
Other name	Tecentriq
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

1200 mg IV q3w

<b>Arm title</b>	Sunitinib
Arm description:	
Sunitinib 50 mg was administered orally once daily on Days 1 to 28 of each 6-week cycle until disease progression. Upon disease progression, participants could crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.	
Arm type	Active comparator
Investigational medicinal product name	Sunitinib
Investigational medicinal product code	
Other name	Sutent
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

50 mg orally once daily for 4 weeks, followed by 2 weeks of rest

<b>Number of subjects in period 1</b>	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib
Started	101	103	101
Treated	100	103	100
Completed	0	0	0
Not completed	101	103	101
Consent withdrawn by subject	5	3	10
Physician decision	-	-	1
Study terminated by Sponsor	38	50	34
Death	52	50	52
Non-compliance	1	-	-
Sponsor Decision	1	-	-
Lost to follow-up	4	-	3
Disease Progression	-	-	1

## Baseline characteristics

### Reporting groups

Reporting group title	Atezolizumab and Bevacizumab
-----------------------	------------------------------

Reporting group description:

Atezolizumab 1200 milligrams (mg) and bevacizumab 15 milligrams per kilogram (mg/kg) were administered as intravenous (IV) infusions every 3 weeks (q3w) on Day 1 and Day 22 of each 6-week cycle until disease progression.

Reporting group title	Atezolizumab
-----------------------	--------------

Reporting group description:

Atezolizumab 1200 mg was administered as IV infusion q3w on Day 1 and Day 22 of each 6-week cycle until disease progression. Upon disease progression, participants (except EU participants) could crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.

Reporting group title	Sunitinib
-----------------------	-----------

Reporting group description:

Sunitinib 50 mg was administered orally once daily on Days 1 to 28 of each 6-week cycle until disease progression. Upon disease progression, participants could crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.

Reporting group values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib
Number of subjects	101	103	101
Age Categorical Units: Subjects			

Age Continuous Units: years arithmetic mean standard deviation	61.1 ± 10.8	60.1 ± 10.2	59.7 ± 10.8
Gender Categorical Units: Subjects			
Female	27	26	22
Male	74	77	79

Reporting group values	Total		
Number of subjects	305		
Age Categorical Units: Subjects			

Age Continuous Units: years arithmetic mean standard deviation	-		
Gender Categorical Units: Subjects			
Female	75		
Male	230		

## Subject analysis sets

Subject analysis set title	Atezolizumab (Crossover)
Subject analysis set type	Intention-to-treat

### Subject analysis set description:

Among the participants assigned to atezolizumab initially, those participants who upon disease progression, crossed over to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination, were included in this group. Atezolizumab 1200 mg and bevacizumab 15 mg/kg were administered as IV infusions q3w on Day 1 and Day 22 of each 6-week cycle.

Subject analysis set title	Sunitinib (Crossover)
Subject analysis set type	Intention-to-treat

### Subject analysis set description:

Among the participants assigned to sunitinib initially, those participants who upon disease progression, crossed over to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination, were included in this group. Atezolizumab 1200 mg and bevacizumab 15 mg/kg were administered as IV infusions q3w on Day 1 and Day 22 of each 6-week cycle.

Reporting group values	Atezolizumab (Crossover)	Sunitinib (Crossover)	
Number of subjects	46	63	
Age Categorical Units: Subjects			

Age Continuous Units: years arithmetic mean standard deviation	59.2 ± 10.6	58.8 ± 12.0	
Gender Categorical Units: Subjects			
Female	9	10	
Male	35	47	

## End points

### End points reporting groups

Reporting group title	Atezolizumab and Bevacizumab
Reporting group description: Atezolizumab 1200 milligrams (mg) and bevacizumab 15 milligrams per kilogram (mg/kg) were administered as intravenous (IV) infusions every 3 weeks (q3w) on Day 1 and Day 22 of each 6-week cycle until disease progression.	
Reporting group title	Atezolizumab
Reporting group description: Atezolizumab 1200 mg was administered as IV infusion q3w on Day 1 and Day 22 of each 6-week cycle until disease progression. Upon disease progression, participants (except EU participants) could crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.	
Reporting group title	Sunitinib
Reporting group description: Sunitinib 50 mg was administered orally once daily on Days 1 to 28 of each 6-week cycle until disease progression. Upon disease progression, participants could crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.	
Subject analysis set title	Atezolizumab (Crossover)
Subject analysis set type	Intention-to-treat
Subject analysis set description: Among the participants assigned to atezolizumab initially, those participants who upon disease progression, crossed over to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination, were included in this group. Atezolizumab 1200 mg and bevacizumab 15 mg/kg were administered as IV infusions q3w on Day 1 and Day 22 of each 6-week cycle.	
Subject analysis set title	Sunitinib (Crossover)
Subject analysis set type	Intention-to-treat
Subject analysis set description: Among the participants assigned to sunitinib initially, those participants who upon disease progression, crossed over to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination, were included in this group. Atezolizumab 1200 mg and bevacizumab 15 mg/kg were administered as IV infusions q3w on Day 1 and Day 22 of each 6-week cycle.	

### Primary: Percentage of Participants with Disease Progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) via Independent Review Committee (IRC) Assessment or Death in Intent-to-Treat (ITT) Population

End point title	Percentage of Participants with Disease Progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) via Independent Review Committee (IRC) Assessment or Death in Intent-to-Treat (ITT) Population <sup>[1]</sup>
End point description: Progressive Disease (PD): at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 millimeters (mm); appearance of one or more new target or non-target lesions; or unequivocal progression of existing non-target lesions. Intent-to-treat (ITT) population included all randomized participants regardless of whether they received any study drug.	
End point type	Primary
End point timeframe: From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)	

#### Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned for this endpoint.

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	101	103	101	
Units: percentage of participants				
number (not applicable)	66.3	59.2	58.4	

## Statistical analyses

No statistical analyses for this end point

## Primary: Progression-Free Survival (PFS) per RECIST v1.1 via IRC Assessment in ITT Population

End point title	Progression-Free Survival (PFS) per RECIST v1.1 via IRC Assessment in ITT Population
-----------------	--

End point description:

PFS was defined as the time from randomization to the first occurrence of PD or death due to any cause. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm; appearance of one or more new target or non-target lesions; or unequivocal progression of existing non-target lesions. Kaplan-Meier methodology was used to estimate PFS. ITT population.

End point type	Primary
----------------	---------

End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	101	103	101	
Units: months				
median (confidence interval 95%)	11.7 (8.4 to 17.3)	6.1 (5.4 to 13.6)	8.4 (7.0 to 14.0)	

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Atezolizumab and Bevacizumab v Sunitinib
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9819
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.69
upper limit	1.45

<b>Statistical analysis title</b>	Statistical Analysis 2
Comparison groups	Atezolizumab v Sunitinib
Number of subjects included in analysis	204
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.358
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.82
upper limit	1.71

**Primary: Percentage of Participants with Disease Progression per RECIST v1.1 via IRC Assessment or Death in Immune Cell 1/2/3 (IC1/2/3) Population**

End point title	Percentage of Participants with Disease Progression per RECIST v1.1 via IRC Assessment or Death in Immune Cell 1/2/3 (IC1/2/3) Population <sup>[2]</sup>
-----------------	--

End point description:

PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm; appearance of one or more new target or non-target lesions; or unequivocal progression of existing non-target lesions. IC1/2/3 population included ITT participants with PD-L1 expression of greater than or equal to ( $\geq$ ) 1% on tumor-infiltrating immune cells.

End point type	Primary
----------------	---------

End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned for this endpoint.

<b>End point values</b>	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	54	60	
Units: percentage of participants				
number (not applicable)	58.0	59.3	68.3	

## Statistical analyses

No statistical analyses for this end point

### Primary: PFS per RECIST v1.1 via IRC Assessment in IC1/2/3 Population

End point title	PFS per RECIST v1.1 via IRC Assessment in IC1/2/3 Population
-----------------	--

End point description:

PFS was defined as the time from randomization to the first occurrence of PD or death due to any cause. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm; appearance of one or more new target or non-target lesions; or unequivocal progression of existing non-target lesions. Kaplan-Meier methodology was used to estimate PFS. IC1/2/3 population.

End point type	Primary
----------------	---------

End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	54	60	
Units: months				
median (confidence interval 95%)	14.7 (8.2 to 25.1)	5.5 (3.0 to 13.9)	7.8 (3.8 to 10.8)	

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Atezolizumab and Bevacizumab v Sunitinib
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0952
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.64
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.38
upper limit	1.08

<b>Statistical analysis title</b>	Statistical Analysis 2
Comparison groups	Atezolizumab v Sunitinib
Number of subjects included in analysis	114
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9172
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.63
upper limit	1.67

### **Secondary: Percentage of Participants with Disease Progression per RECIST v1.1 via IRC Assessment or Death in Participants who Have Tumors with Higher Than Median Expression of an Immune Gene Signature**

End point title	Percentage of Participants with Disease Progression per RECIST v1.1 via IRC Assessment or Death in Participants who Have Tumors with Higher Than Median Expression of an Immune Gene Signature
-----------------	--

End point description:

PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm; appearance of one or more new target or non-target lesions; or unequivocal progression of existing non-target lesions. Biomarker evaluable population included ITT participants whose tumor samples had sufficient material available for gene signature expression analyses. Participants with higher than median expression of an immune gene signature were included in this analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

<b>End point values</b>	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	44	42	
Units: percentage of participants				
number (not applicable)	55.6	61.4	73.8	

## **Statistical analyses**

## Secondary: PFS per RECIST v1.1 via IRC Assessment in Participants who Have Tumors with Higher Than Median Expression of an Immune Gene Signature

End point title	PFS per RECIST v1.1 via IRC Assessment in Participants who Have Tumors with Higher Than Median Expression of an Immune Gene Signature
-----------------	---

### End point description:

PFS was defined as the time from randomization to the first occurrence of PD or death due to any cause. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm; appearance of one or more new target or non-target lesions; or unequivocal progression of existing non-target lesions. Kaplan-Meier methodology was used to estimate PFS. Biomarker evaluable population. Participants with higher than median expression of an immune gene signature were included in this analysis. '99999' indicates that data could not be estimated due to high number of censored participants.

End point type	Secondary
----------------	-----------

### End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	44	42	
Units: months				
median (confidence interval 95%)	17.5 (10.3 to 99999)	5.7 (3.2 to 16.7)	7.1 (4.2 to 8.7)	

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Atezolizumab and Bevacizumab v Sunitinib
Number of subjects included in analysis	87
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0153
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.48
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.26
upper limit	0.87

Statistical analysis title	Statistical Analysis 2
----------------------------	------------------------

Comparison groups	Atezolizumab v Sunitinib
Number of subjects included in analysis	86
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5545
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.48
upper limit	1.46

---

**Secondary: Percentage of Participants with Disease Progression per RECIST v1.1 via Investigator Assessment or Death in Participants who Have Tumors with Higher Than Median Expression of an Immune Gene Signature**

---

End point title	Percentage of Participants with Disease Progression per RECIST v1.1 via Investigator Assessment or Death in Participants who Have Tumors with Higher Than Median Expression of an Immune Gene Signature
-----------------	---

End point description:

PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm; appearance of one or more new target or non-target lesions; or unequivocal progression of existing non-target lesions. Biomarker evaluable population. Participants with higher than median expression of an immune gene signature were included in this analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

---

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	44	42	
Units: percentage of participants				
number (not applicable)	57.8	77.3	83.3	

**Statistical analyses**

---

No statistical analyses for this end point

---

**Secondary: PFS per RECIST v1.1 via Investigator Assessment in Participants who Have Tumors with Higher Than Median Expression of an Immune Gene Signature**

---

End point title	PFS per RECIST v1.1 via Investigator Assessment in
-----------------	--

---

End point description:

PFS was defined as the time from randomization to the first occurrence of PD or death due to any cause. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm; appearance of one or more new target or non-target lesions; or unequivocal progression of existing non-target lesions. Kaplan-Meier methodology was used to estimate PFS. Biomarker evaluable population. Participants with higher than median expression of an immune gene signature were included in this analysis. '99999' indicates that data could not be estimated due to high number of censored participants.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	45	44	42	
Units: months				
median (confidence interval 95%)	16.6 (8.2 to 99999)	5.5 (3.0 to 11.1)	6.8 (5.4 to 8.7)	

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Atezolizumab and Bevacizumab v Sunitinib
Number of subjects included in analysis	87
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0086
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.49
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.28
upper limit	0.84

Statistical analysis title	Statistical Analysis 2
Comparison groups	Atezolizumab v Sunitinib

Number of subjects included in analysis	86
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7675
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	1.53

---

**Secondary: Percentage of Participants with Disease Progression per RECIST v1.1 via IRC Assessment or Death in Participants who Have Tumors with Higher Than the 33rd Percentile Expression of an Immune Gene Signature**

---

End point title	Percentage of Participants with Disease Progression per RECIST v1.1 via IRC Assessment or Death in Participants who Have Tumors with Higher Than the 33rd Percentile Expression of an Immune Gene Signature
-----------------	---

End point description:

PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm; appearance of one or more new target or non-target lesions; or unequivocal progression of existing non-target lesions. Biomarker evaluable population. Participants with higher than the 33rd percentile expression of an immune gene signature were included in this analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

---

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	61	55	60	
Units: percentage of participants				
number (not applicable)	59.0	58.2	65.0	

## Statistical analyses

No statistical analyses for this end point

---



---

**Secondary: PFS per RECIST v1.1 via IRC Assessment in Participants who Have Tumors with Higher Than the 33rd Percentile Expression of an Immune Gene Signature**

---

End point title	PFS per RECIST v1.1 via IRC Assessment in Participants who Have Tumors with Higher Than the 33rd Percentile Expression
-----------------	--

## End point description:

PFS was defined as the time from randomization to the first occurrence of PD or death due to any cause. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm; appearance of one or more new target or non-target lesions; or unequivocal progression of existing non-target lesions. Kaplan-Meier methodology was used to estimate PFS. Biomarker evaluable population. Participants with higher than the 33rd percentile expression of an immune gene signature were included in this analysis.

End point type	Secondary
----------------	-----------

## End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	61	55	60	
Units: months				
median (confidence interval 95%)	13.8 (8.3 to 25.1)	5.7 (5.4 to 17.3)	8.2 (5.7 to 11.4)	

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Atezolizumab and Bevacizumab v Sunitinib
Number of subjects included in analysis	121
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1973
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.72
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.44
upper limit	1.18

Statistical analysis title	Statistical Analysis 2
Comparison groups	Atezolizumab v Sunitinib

Number of subjects included in analysis	115
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7738
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.65
upper limit	1.76

---

**Secondary: Percentage of Participants with Disease Progression per RECIST v1.1 via Investigator Assessment or Death in Participants who Have Tumors with Higher Than the 33rd Percentile Expression of an Immune Gene Signature**

---

End point title	Percentage of Participants with Disease Progression per RECIST v1.1 via Investigator Assessment or Death in Participants who Have Tumors with Higher Than the 33rd Percentile Expression of an Immune Gene Signature
-----------------	--

End point description:

PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm; appearance of one or more new target or non-target lesions; or unequivocal progression of existing non-target lesions. Biomarker evaluable population. Participants with higher than the 33rd percentile expression of an immune gene signature were included in this analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

---

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	61	55	60	
Units: percentage of participants				
number (not applicable)	63.9	76.4	78.3	

**Statistical analyses**

---

No statistical analyses for this end point

---

**Secondary: PFS per RECIST v1.1 via Investigator Assessment in Participants who Have Tumors with Higher Than the 33rd Percentile Expression of an Immune Gene Signature**

---

End point title	PFS per RECIST v1.1 via Investigator Assessment in Participants who Have Tumors with Higher Than the 33rd
-----------------	---

---

## End point description:

PFS was defined as the time from randomization to the first occurrence of PD or death due to any cause. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm; appearance of one or more new target or non-target lesions; or unequivocal progression of existing non-target lesions. Kaplan-Meier methodology was used to estimate PFS. Biomarker evaluable population. Participants with higher than the 33rd percentile expression of an immune gene signature were included in this analysis.

End point type	Secondary
----------------	-----------

## End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	61	55	60	
Units: months				
median (confidence interval 95%)	11.1 (8.1 to 19.3)	5.5 (3.0 to 10.9)	7.1 (5.8 to 11.3)	

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Atezolizumab and Bevacizumab v Sunitinib
Number of subjects included in analysis	121
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.083
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.68
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.43
upper limit	1.06

Statistical analysis title	Statistical Analysis 2
Comparison groups	Atezolizumab v Sunitinib

Number of subjects included in analysis	115
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7141
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7
upper limit	1.69

### Secondary: Percentage of Participants with Disease Progression per RECIST v1.1 via Investigator Assessment or Death in ITT Population

End point title	Percentage of Participants with Disease Progression per RECIST v1.1 via Investigator Assessment or Death in ITT Population
-----------------	--

End point description:

PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm; appearance of one or more new target or non-target lesions; or unequivocal progression of existing non-target lesions. ITT population.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	101	103	101	
Units: percentage of participants				
number (not applicable)	71.3	75.7	75.2	

### Statistical analyses

No statistical analyses for this end point

### Secondary: PFS per RECIST v1.1 via Investigator Assessment in ITT Population

End point title	PFS per RECIST v1.1 via Investigator Assessment in ITT Population
-----------------	---

End point description:

PFS was defined as the time from randomization to the first occurrence of PD or death due to any cause. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm; appearance of one or more new target or non-target lesions; or unequivocal progression of existing non-target lesions. Kaplan-

Meier methodology was used to estimate PFS. ITT population.

End point type	Secondary
End point timeframe:	
From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)	

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	101	103	101	
Units: months				
median (confidence interval 95%)	11.1 (8.2 to 13.5)	5.5 (3.0 to 8.4)	7.8 (5.7 to 11.2)	

### Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Atezolizumab and Bevacizumab v Sunitinib
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2541
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.59
upper limit	1.15

Statistical analysis title	Statistical Analysis 2
Comparison groups	Atezolizumab v Sunitinib
Number of subjects included in analysis	204
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3103
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.18

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.86
upper limit	1.63

### Secondary: Percentage of Participants with Disease Progression per RECIST v1.1 via Investigator Assessment or Death in IC1/2/3 Population

End point title	Percentage of Participants with Disease Progression per RECIST v1.1 via Investigator Assessment or Death in IC1/2/3 Population
-----------------	--

End point description:

PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm; appearance of one or more new target or non-target lesions; or unequivocal progression of existing non-target lesions. IC1/2/3 population.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	54	60	
Units: percentage of participants				
number (not applicable)	66.0	74.1	81.7	

### Statistical analyses

No statistical analyses for this end point

### Secondary: PFS per RECIST v1.1 via Investigator Assessment in IC1/2/3 Population

End point title	PFS per RECIST v1.1 via Investigator Assessment in IC1/2/3 Population
-----------------	---

End point description:

PFS was defined as the time from randomization to the first occurrence of PD or death due to any cause. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm; appearance of one or more new target or non-target lesions; or unequivocal progression of existing non-target lesions. Kaplan-Meier methodology was used to estimate PFS. IC1/2/3 population.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

<b>End point values</b>	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	54	60	
Units: months				
median (confidence interval 95%)	11.1 (8.1 to 16.7)	5.5 (3.0 to 10.9)	7.0 (5.6 to 11.2)	

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Comparison groups	Atezolizumab and Bevacizumab v Sunitinib
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0351
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.37
upper limit	0.97

<b>Statistical analysis title</b>	Statistical Analysis 2
Comparison groups	Atezolizumab v Sunitinib
Number of subjects included in analysis	114
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9769
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.64
upper limit	1.54

## Secondary: Percentage of Participants with Objective Response (Complete Response [CR] or Partial Response [PR]) per RECIST v1.1 via IRC Assessment in ITT Population

End point title	Percentage of Participants with Objective Response (Complete Response [CR] or Partial Response [PR]) per RECIST v1.1 via IRC Assessment in ITT Population
-----------------	---

End point description:

Objective Response was defined as CR or PR. CR: disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker level; or reduction in short axis of any pathological lymph nodes (whether target or non-target) to less than (<) 10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters; or persistence of one or more non-target lesion(s) and/or (if applicable) maintenance of tumor marker level above the normal limits. ITT population.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	101	103	101	
Units: percentage of participants				
number (confidence interval 95%)	31.7 (22.78 to 41.69)	25.2 (17.20 to 34.76)	28.7 (20.15 to 38.57)	

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Atezolizumab and Bevacizumab v Sunitinib
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6492
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in response rates
Point estimate	2.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.68
upper limit	16.62

Statistical analysis title	Statistical Analysis 2
Comparison groups	Atezolizumab v Sunitinib

Number of subjects included in analysis	204
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5433
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in response rates
Point estimate	-3.47
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.63
upper limit	9.69

### Secondary: Percentage of Participants with Objective Response per RECIST v1.1 via IRC Assessment in IC1/2/3 Population

End point title	Percentage of Participants with Objective Response per RECIST v1.1 via IRC Assessment in IC1/2/3 Population
-----------------	---

End point description:

Objective Response was defined as CR or PR. CR: disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker level; or reduction in short axis of any pathological lymph nodes (whether target or non-target) to <10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters; or persistence of one or more non-target lesion(s) and/or (if applicable) maintenance of tumor marker level above the normal limits. IC1/2/3 population.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	54	60	
Units: percentage of participants				
number (confidence interval 95%)	46.0 (31.81 to 60.68)	27.8 (16.46 to 41.64)	26.7 (16.07 to 39.66)	

### Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Atezolizumab and Bevacizumab v Sunitinib

Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0141
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in response rates
Point estimate	19.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.28
upper limit	38.94

<b>Statistical analysis title</b>	Statistical Analysis 2
Comparison groups	Atezolizumab v Sunitinib
Number of subjects included in analysis	114
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8719
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in response rates
Point estimate	1.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.02
upper limit	19.24

### **Secondary: Percentage of Participants with Objective Response per RECIST v1.1 via Investigator Assessment in ITT Population**

End point title	Percentage of Participants with Objective Response per RECIST v1.1 via Investigator Assessment in ITT Population
-----------------	--

End point description:

Objective Response was defined as CR or PR. CR: disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker level; or reduction in short axis of any pathological lymph nodes (whether target or non-target) to <10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters; or persistence of one or more non-target lesion(s) and/or (if applicable) maintenance of tumor marker level above the normal limits. ITT population.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

<b>End point values</b>	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	101	103	101	
Units: percentage of participants				
number (confidence interval 95%)	34.7 (25.46 to 44.77)	23.3 (15.54 to 32.66)	32.7 (23.67 to 42.72)	

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Comparison groups	Atezolizumab and Bevacizumab v Sunitinib
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8068
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in response rates
Point estimate	1.98
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.04
upper limit	16

<b>Statistical analysis title</b>	Statistical Analysis 2
Comparison groups	Atezolizumab v Sunitinib
Number of subjects included in analysis	204
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1321
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in response rates
Point estimate	-9.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.61
upper limit	3.87

## Secondary: Percentage of Participants with Objective Response per RECIST v1.1 via Investigator Assessment in IC1/2/3 Population

End point title	Percentage of Participants with Objective Response per RECIST v1.1 via Investigator Assessment in IC1/2/3 Population
-----------------	--

**End point description:**

Objective Response was defined as CR or PR. CR: disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker level; or reduction in short axis of any pathological lymph nodes (whether target or non-target) to <10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters; or persistence of one or more non-target lesion(s) and/or (if applicable) maintenance of tumor marker level above the normal limits. IC1/2/3 population.

End point type	Secondary
----------------	-----------

**End point timeframe:**

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	54	60	
Units: percentage of participants				
number (confidence interval 95%)	48.0 (33.66 to 62.58)	25.9 (14.96 to 39.65)	28.3 (17.45 to 41.44)	

**Statistical analyses**

Statistical analysis title	Statistical Analysis 1
Comparison groups	Atezolizumab and Bevacizumab v Sunitinib
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0199
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in response rates
Point estimate	19.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1
upper limit	39.44

Statistical analysis title	Statistical Analysis 2
Comparison groups	Atezolizumab v Sunitinib

Number of subjects included in analysis	114
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7836
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in response rates
Point estimate	-2.41
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.5
upper limit	15.68

### Secondary: Percentage of Participants with Objective Response per Modified RECIST via Investigator Assessment in ITT Population

End point title	Percentage of Participants with Objective Response per Modified RECIST via Investigator Assessment in ITT Population
-----------------	--

End point description:

Objective Response was defined as CR or PR. CR: disappearance of all target and non-target lesions; or reduction in short axis of any pathological lymph nodes (whether target or non-target) to <10 mm. PR: at least a 30% decrease in the sum of diameters of target and all new measurable lesions, taking as reference the baseline sum of diameters, in absence of CR. ITT population.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	101	103	101	
Units: percentage of participants				
number (confidence interval 95%)	37.6 (28.18 to 47.82)	25.2 (17.20 to 34.76)	33.7 (24.56 to 43.75)	

### Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Atezolizumab and Bevacizumab v Sunitinib

Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6231
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in response rates
Point estimate	3.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.23
upper limit	18.15

<b>Statistical analysis title</b>	Statistical Analysis 2
Comparison groups	Atezolizumab v Sunitinib
Number of subjects included in analysis	204
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1816
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in response rates
Point estimate	-8.42
Confidence interval	
level	95 %
sides	2-sided
lower limit	-21.86
upper limit	5.02

### **Secondary: Percentage of Participants with Objective Response per Modified RECIST via Investigator Assessment in IC1/2/3 Population**

End point title	Percentage of Participants with Objective Response per Modified RECIST via Investigator Assessment in IC1/2/3 Population
-----------------	--

End point description:

Objective Response was defined as CR or PR. CR: disappearance of all target and non-target lesions; or reduction in short axis of any pathological lymph nodes (whether target or non-target) to <10 mm. PR: at least a 30% decrease in the sum of diameters of target and all new measurable lesions, taking as reference the baseline sum of diameters, in absence of CR. IC1/2/3 population.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

<b>End point values</b>	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	54	60	
Units: percentage of participants				
number (confidence interval 95%)	52.0 (37.42 to 66.34)	27.8 (16.46 to 41.64)	30.0 (18.85 to 43.21)	

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Comparison groups	Atezolizumab and Bevacizumab v Sunitinib
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0111
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in response rates
Point estimate	22
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.11
upper limit	41.89

<b>Statistical analysis title</b>	Statistical Analysis 2
Comparison groups	Atezolizumab v Sunitinib
Number of subjects included in analysis	114
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8209
Method	Cochran-Mantel-Haenszel
Parameter estimate	Difference in response rates
Point estimate	-2.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.63
upper limit	16.19

## Secondary: Percentage of Participants with Disease Progression per Modified RECIST via Investigator Assessment or Death in ITT Population

End point title	Percentage of Participants with Disease Progression per Modified RECIST via Investigator Assessment or Death in ITT Population
-----------------	--

**End point description:**

PD: at least a 20% increase in the sum of diameters of all target and new measurable lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm. ITT population.

End point type	Secondary
----------------	-----------

**End point timeframe:**

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	101	103	101	
Units: percentage of participants				
number (not applicable)	60.4	61.2	63.4	

**Statistical analyses**

No statistical analyses for this end point

**Secondary: PFS per Modified RECIST via Investigator Assessment in ITT Population**

End point title	PFS per Modified RECIST via Investigator Assessment in ITT Population
-----------------	---

**End point description:**

PFS was defined as the time from randomization to the first occurrence of PD or death due to any cause. PD: at least a 20% increase in the sum of diameters of all target and new measurable lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm. Kaplan-Meier methodology was used to estimate PFS. ITT population.

End point type	Secondary
----------------	-----------

**End point timeframe:**

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	101	103	101	
Units: months				
median (confidence interval 95%)	16.7 (11.4 to 22.6)	10.9 (7.9 to 14.0)	9.9 (8.1 to 14.1)	

**Statistical analyses**

<b>Statistical analysis title</b>	Statistical Analysis 1
Comparison groups	Atezolizumab and Bevacizumab v Sunitinib
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0863
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.72
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.5
upper limit	1.05

<b>Statistical analysis title</b>	Statistical Analysis 2
Comparison groups	Atezolizumab v Sunitinib
Number of subjects included in analysis	204
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5922
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.77
upper limit	1.57

### **Secondary: Percentage of Participants with Disease Progression per Modified RECIST via Investigator Assessment or Death in IC1/2/3 Population**

End point title	Percentage of Participants with Disease Progression per Modified RECIST via Investigator Assessment or Death in IC1/2/3 Population
End point description: PD: at least a 20% increase in the sum of diameters of all target and new measurable lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm. IC1/2/3 population.	
End point type	Secondary
End point timeframe: From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)	

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	54	60	
Units: percentage of participants				
number (not applicable)	52.0	59.3	75.0	

## Statistical analyses

No statistical analyses for this end point

## Secondary: PFS per Modified RECIST via Investigator Assessment in IC1/2/3 Population

End point title	PFS per Modified RECIST via Investigator Assessment in IC1/2/3 Population
-----------------	---

End point description:

PFS was defined as the time from randomization to the first occurrence of PD or death due to any cause. PD: at least a 20% increase in the sum of diameters of all target and new measurable lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm. Kaplan-Meier methodology was used to estimate PFS. IC1/2/3 population. '99999' indicates that data could not be estimated due to high number of censored participants.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	54	60	
Units: months				
median (confidence interval 95%)	21.7 (11.1 to 99999)	10.9 (5.4 to 14.0)	8.4 (5.8 to 11.3)	

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Atezolizumab and Bevacizumab v Sunitinib
Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0021
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.43

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.25
upper limit	0.75

<b>Statistical analysis title</b>	Statistical Analysis 2
Comparison groups	Atezolizumab v Sunitinib
Number of subjects included in analysis	114
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6566
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	1.44

### Secondary: Duration of Response (DOR) per RECIST v1.1 via IRC Assessment in ITT Population

End point title	Duration of Response (DOR) per RECIST v1.1 via IRC Assessment in ITT Population
-----------------	---

#### End point description:

DOR was defined as the time from first observation of an objective response (CR or PR) until first observation of PD. CR, PR, and PD have been defined in previous endpoints, and are not repeated here due to space constraint. Kaplan-Meier methodology was used to estimate DOR. ITT population. 'Number of Subjects Analyzed'=participants evaluable for this outcome measure. '99999' indicates that data could not be estimated due to high number of censored participants.

End point type	Secondary
----------------	-----------

#### End point timeframe:

From CR or PR until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32	26	29	
Units: months				
median (confidence interval 95%)	22.1 (19.4 to 99999)	99999 (23.4 to 99999)	99999 (99999 to 99999)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: DOR per RECIST v1.1 via Investigator Assessment in ITT Population

End point title	DOR per RECIST v1.1 via Investigator Assessment in ITT Population
-----------------	---

End point description:

DOR was defined as the time from first observation of an objective response (CR or PR) until first observation of PD. CR, PR, and PD have been defined in previous endpoints, and are not repeated here due to space constraint. Kaplan-Meier methodology was used to estimate DOR. ITT population. 'Number of Subjects Analyzed'=participants evaluable for this outcome measure. '99999' indicates that data could not be estimated due to high number of censored participants.

End point type	Secondary
----------------	-----------

End point timeframe:

From CR or PR until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	35	24	33	
Units: months				
median (confidence interval 95%)	99999 (19.4 to 99999)	99999 (99999 to 99999)	14.2 (13.0 to 99999)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: DOR per RECIST v1.1 via IRC Assessment in IC1/2/3 Population

End point title	DOR per RECIST v1.1 via IRC Assessment in IC1/2/3 Population
-----------------	--

End point description:

DOR was defined as the time from first observation of an objective response (CR or PR) until first observation of PD. CR, PR, and PD have been defined in previous endpoints, and are not repeated here due to space constraint. Kaplan-Meier methodology was used to estimate DOR. IC1/2/3 population. 'Number of Subjects Analyzed'=participants evaluable for this outcome measure. '99999' indicates that data could not be estimated due to high number of censored participants.

End point type	Secondary
----------------	-----------

End point timeframe:

From CR or PR until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	23	15	16	
Units: months				
median (confidence interval 95%)	22.1 (19.4 to 99999)	99999 (23.4 to 99999)	99999 (12.0 to 99999)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: DOR per RECIST v1.1 via Investigator Assessment in IC1/2/3 Population

End point title	DOR per RECIST v1.1 via Investigator Assessment in IC1/2/3 Population
-----------------	---

End point description:

DOR was defined as the time from first observation of an objective response (CR or PR) until first observation of PD. CR, PR, and PD have been defined in previous endpoints, and are not repeated here due to space constraint. Kaplan-Meier methodology was used to estimate DOR. IC1/2/3 population. 'Number of Subjects Analyzed'=participants evaluable for this outcome measure. '99999' indicates that data could not be estimated due to high number of censored participants.

End point type	Secondary
----------------	-----------

End point timeframe:

From CR or PR until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	24	14	17	
Units: months				
median (confidence interval 95%)	22.4 (13.8 to 99999)	99999 (99999 to 99999)	14.1 (11.1 to 99999)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: DOR per Modified RECIST via Investigator Assessment in ITT Population

End point title	DOR per Modified RECIST via Investigator Assessment in ITT Population
-----------------	---

End point description:

DOR was defined as the time from first observation of an objective response (CR or PR) until first observation of PD. CR, PR, and PD have been defined in previous endpoints, and are not repeated here due to space constraint. Kaplan-Meier methodology was used to estimate DOR. ITT population. 'Number of Subjects Analyzed'=participants evaluable for this outcome measure. '99999' indicates that data could not be estimated due to high number of censored participants.

End point type	Secondary
----------------	-----------

End point timeframe:

From CR or PR until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	38	26	34	
Units: months				
median (confidence interval 95%)	99999 (19.8 to 99999)	99999 (99999 to 99999)	16.6 (13.6 to 99999)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: DOR per Modified RECIST via Investigator Assessment in IC1/2/3 Population

End point title	DOR per Modified RECIST via Investigator Assessment in IC1/2/3 Population
-----------------	---

End point description:

DOR was defined as the time from first observation of an objective response (CR or PR) until first observation of PD. CR, PR, and PD have been defined in previous endpoints, and are not repeated here due to space constraint. Kaplan-Meier methodology was used to estimate DOR. IC1/2/3 population. 'Number of Subjects Analyzed'=participants evaluable for this outcome measure. '99999' indicates that data could not be estimated due to high number of censored participants.

End point type	Secondary
----------------	-----------

End point timeframe:

From CR or PR until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	26	15	18	
Units: months				
median (confidence interval 95%)	22.4 (19.4 to 99999)	99999 (99999 to 99999)	16.6 (11.3 to 99999)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants who Died in ITT Population

End point title	Percentage of Participants who Died in ITT Population
-----------------	---

End point description:

ITT population.

End point type	Secondary
----------------	-----------

End point timeframe:

Randomization until death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	101	103	101	
Units: percentage of participants				
number (not applicable)	38.6	35.0	30.7	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Overall Survival (OS) in ITT Population

End point title	Overall Survival (OS) in ITT Population
-----------------	---

End point description:

OS was defined as the time from the date of randomization to the date of death due to any cause. Kaplan-Meier methodology was used to estimate OS. ITT population. '99999' indicates that data could not be estimated due to high number of censored participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Randomization until death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	101	103	101	
Units: months				
median (confidence interval 95%)	99999 (23.9 to 99999)	99999 (30.2 to 99999)	99999 (27.2 to 99999)	

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Atezolizumab and Bevacizumab v Sunitinib
Number of subjects included in analysis	202
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2867
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.8
upper limit	2.13

Statistical analysis title	Statistical Analysis 2
Comparison groups	Atezolizumab v Sunitinib
Number of subjects included in analysis	204
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8039
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.65
upper limit	1.73

## Secondary: Percentage of Participants who Died in IC1/2/3 Population

End point title	Percentage of Participants who Died in IC1/2/3 Population
End point description: IC1/2/3 population.	

End point type	Secondary
End point timeframe:	
Randomization until death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)	

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	54	60	
Units: percentage of participants				
number (not applicable)	38.0	39.8	35.0	

### Statistical analyses

No statistical analyses for this end point

### Secondary: OS in IC1/2/3 Population

End point title	OS in IC1/2/3 Population
End point description:	
OS was defined as the time from the date of randomization to the date of death due to any cause. Kaplan-Meier methodology was used to estimate OS. IC1/2/3 population. '99999' indicates that data could not be estimated due to high number of censored participants.	
End point type	Secondary
End point timeframe:	
Randomization until death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)	

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	54	60	
Units: months				
median (confidence interval 95%)	27.3 (24.6 to 99999)	30.2 (23.3 to 99999)	99999 (22.4 to 99999)	

### Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Atezolizumab and Bevacizumab v Sunitinib

Number of subjects included in analysis	110
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7879
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.47
upper limit	1.78

<b>Statistical analysis title</b>	Statistical Analysis 2
Comparison groups	Atezolizumab v Sunitinib
Number of subjects included in analysis	114
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9065
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.52
upper limit	1.8

### **Secondary: Percentage of Participants with Objective Response per RECIST v1.1 via Investigator Assessment in Crossover Population**

End point title	Percentage of Participants with Objective Response per RECIST v1.1 via Investigator Assessment in Crossover Population
-----------------	--

#### **End point description:**

Objective Response was defined as CR or PR. CR: disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker level; or reduction in short axis of any pathological lymph nodes (whether target or non-target) to <10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters; or persistence of one or more non-target lesion(s) and/or (if applicable) maintenance of tumor marker level above the normal limits. Crossover population included participants in atezolizumab or sunitinib arms who had crossed over to the atezolizumab and bevacizumab arm. 'Number of Subjects Analyzed'=participants evaluable for this outcome measure.

End point type	Secondary
----------------	-----------

#### **End point timeframe:**

From start of crossover treatment until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab (Crossover)	Sunitinib (Crossover)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	41	54		
Units: percentage of participants				
number (confidence interval 95%)	24.4 (12.36 to 40.30)	27.8 (16.46 to 41.64)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: DOR per RECIST v1.1 via Investigator Assessment in Crossover Population

End point title	DOR per RECIST v1.1 via Investigator Assessment in Crossover Population
-----------------	---

End point description:

DOR was defined as the time from first observation of an objective response (CR or PR) until first observation of PD. CR, PR, and PD have been defined in previous endpoints, and are not repeated here due to space constraint. Kaplan-Meier methodology was used to estimate DOR. Crossover population. 'Number of Subjects Analyzed'=participants evaluable for this outcome measure. '99999' indicates that data could not be estimated due to high number of censored participants.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of crossover treatment until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab (Crossover)	Sunitinib (Crossover)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	10	15		
Units: months				
median (confidence interval 95%)	99999 (7.2 to 99999)	99999 (11.1 to 99999)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants with Disease Progression per RECIST v1.1 via Investigator Assessment or Death in Crossover Population

End point title	Percentage of Participants with Disease Progression per RECIST v1.1 via Investigator Assessment or Death in Crossover Population
-----------------	--

End point description:

PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm; appearance of one or more new target or non-target lesions; or unequivocal progression of existing non-target lesions. Crossover population.

End point type	Secondary
End point timeframe:	
From start of crossover treatment until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)	

End point values	Atezolizumab (Crossover)	Sunitinib (Crossover)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	44	57		
Units: percentage of participants				
number (not applicable)	59.1	68.4		

### Statistical analyses

No statistical analyses for this end point

### Secondary: PFS per RECIST v1.1 via Investigator Assessment in Crossover Population

End point title	PFS per RECIST v1.1 via Investigator Assessment in Crossover Population
-----------------	---

End point description:

PFS was defined as the time from randomization to the first occurrence of PD or death due to any cause. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm; appearance of one or more new target or non-target lesions; or unequivocal progression of existing non-target lesions. Kaplan-Meier methodology was used to estimate PFS. Crossover population.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of crossover treatment until disease progression or death due to any cause (until data cut-off date 17 October 2016, up to approximately 2.75 years)

End point values	Atezolizumab (Crossover)	Sunitinib (Crossover)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	44	57		
Units: months				
median (confidence interval 95%)	12.6 (6.0 to 17.7)	8.3 (3.1 to 11.2)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants with Anti-Therapeutic Antibodies (ATA) to

## Atezolizumab

End point title	Percentage of Participants with Anti-Therapeutic Antibodies (ATA) to Atezolizumab <sup>[3]</sup>
-----------------	--

End point description:

This outcome measure was planned to be analyzed in 'Atezolizumab' and 'Atezolizumab and Bevacizumab' arms only. ATA evaluable population included participants at baseline who had a baseline ATA sample and post-baseline participants who had at least one ATA sample and had received at least one dose of study treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 1 until treatment discontinuation (until data cut-off date 17 October 2016, up to approximately 2.75 years) (1 cycle=6 weeks)

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was planned to be evaluated for the reported arms only.

End point values	Atezolizumab and Bevacizumab	Atezolizumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	97	96		
Units: percentage of participants				
number (not applicable)	34.0	25.0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maximum Serum Concentration (Cmax) of Atezolizumab

End point title	Maximum Serum Concentration (Cmax) of Atezolizumab <sup>[4]</sup>
-----------------	---

End point description:

The pharmacokinetic (PK) evaluable population included participants who received at least one dose of study drug and had sufficient PK sample collected within the time specified in the protocol. 'Number of Subjects Analyzed'=participants evaluable for this outcome measure.

End point type	Secondary
----------------	-----------

End point timeframe:

30 minutes after end of infusion on Cycle 1 Day 1 (1 cycle=6 weeks) (infusion length for first dose=60 minutes)

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis was planned for this endpoint.

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Atezolizumab (Crossover)	Sunitinib (Crossover)
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	95	93	41	53
Units: micrograms per milliliter (mcg/mL)				
arithmetic mean (standard deviation)	335 (± 86.0)	358 (± 93.1)	418 (± 114)	314 (± 87.1)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Minimum Serum Concentration (Cmin) of Atezolizumab

End point title	Minimum Serum Concentration (Cmin) of Atezolizumab <sup>[5]</sup>
-----------------	---

End point description:

PK evaluable population. 'Number of Subjects Analyzed'=participants evaluable for this outcome measure. 'n'=participants evaluable for this outcome measure at specified timepoint for each arm respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-infusion (0 hour) on Day 1 of Cycles 2 and 4; Day 22 of Cycles 1, 2, and 4 (1 cycle=6 weeks) (infusion length=30-60 minutes)

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis was planned for this endpoint.

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Atezolizumab (Crossover)	Sunitinib (Crossover)
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	98	94	42	52
Units: mcg/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 22 (n=98, 94, 42, 52)	72.6 (± 29.5)	79.9 (± 26.1)	174 (± 121)	73.2 (± 31.5)
Cycle 2 Day 1 (n=89, 88, 38, 49)	122 (± 50.4)	125 (± 47.4)	158 (± 101)	106 (± 45.2)
Cycle 2 Day 22 (n=85, 88, 38, 44)	152 (± 65.3)	159 (± 84.6)	164 (± 70.7)	141 (± 85.5)
Cycle 4 Day 1 (n=79, 66, 28, 34)	183 (± 90.5)	192 (± 77.6)	154 (± 62.7)	174 (± 75.7)
Cycle 4 Day 22 (n=71, 65, 25, 29)	190 (± 86.3)	200 (± 90.0)	163 (± 70.5)	172 (± 78.8)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Cmax of Bevacizumab

End point title	Cmax of Bevacizumab <sup>[6]</sup>
-----------------	------------------------------------

End point description:

PK evaluable population. 'Number of Subjects Analyzed'=participants evaluable for this outcome measure.

End point type	Secondary
----------------	-----------

End point timeframe:

30 minutes after end of infusion on Day 1 of Cycles 1 and 2 (1 cycle=6 weeks) (infusion length=30-90 minutes)

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.  
Justification: No statistical analysis was planned for this endpoint.

End point values	Atezolizumab and Bevacizumab	Atezolizumab (Crossover)	Sunitinib (Crossover)	
Subject group type	Reporting group	Subject analysis set	Subject analysis set	
Number of subjects analysed	86	34	44	
Units: mcg/mL				
arithmetic mean (standard deviation)	89.8 (± 39.4)	433 (± 115)	455 (± 106)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Cmin of Bevacizumab

End point title	Cmin of Bevacizumab <sup>[7]</sup>
End point description: PK evaluable population. 'Number of Subjects Analyzed'=participants evaluable for this outcome measure.	
End point type	Secondary
End point timeframe: For Atezolizumab and Bevacizumab Arm: at First-line treatment discontinuation (up to approximately 2.75 years); For Crossover Arms: pre-infusion (0 hour) on Day 1 of Cycle 2 (1 cycle=6 weeks) (infusion length=30-90 minutes)	

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.  
Justification: No statistical analysis was planned for this endpoint.

End point values	Atezolizumab and Bevacizumab	Atezolizumab (Crossover)	Sunitinib (Crossover)	
Subject group type	Reporting group	Subject analysis set	Subject analysis set	
Number of subjects analysed	42	39	42	
Units: mcg/mL				
arithmetic mean (standard deviation)	75.2 (± 72.1)	101 (± 48.7)	95.9 (± 43.9)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: M.D. Anderson Symptom Inventory (MDASI) Interference Score

End point title	M.D. Anderson Symptom Inventory (MDASI) Interference Score
End point description: MDASI questionnaire comprises of 2 parts:symptoms (16 items), interference with daily life (6 items). Participants were asked to rate how much their symptoms interfered with general activity, mood, work,	

relations with other people, walking, enjoyment of life during last 24 hours. Each item in interference score was answered on scale of 0 (did not interfere) to 10 (interfered completely). Mean score of 6 items was reported on scale of 0 (did not interfere) to 10 (interfered completely). Patient Reported Outcome (PRO)-evaluable population: randomized participants who had non-missing baseline assessment and at least 1 post-baseline assessment. 'Overall Number of Participants Analyzed'=participants evaluable for this outcome. 'n'=participants evaluable for this outcome at specified timepoint for each arm, respectively. '999999' indicates that standard deviation was not estimable for single participant. '999' indicates that data were not estimable as there were no evaluable participants.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 1 and 22 of Cycles 1 to 24; Day 1 of Cycle 25; treatment discontinuation (up to approximately 2.75 years) (1 cycle=6 weeks)

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	96	95	93	
Units: units on a scale				
arithmetic mean (standard deviation)				
Cycle 1 Day 1 (n=96, 95, 93)	1.60 (± 1.97)	1.38 (± 2.03)	1.79 (± 2.39)	
Cycle 1 Day 22 (n=93, 88, 88)	2.08 (± 2.34)	1.26 (± 2.07)	3.16 (± 2.65)	
Cycle 2 Day 1 (n=86, 82, 80)	1.56 (± 1.82)	1.20 (± 1.72)	1.83 (± 2.19)	
Cycle 2 Day 22 (n=82, 80, 77)	1.57 (± 1.83)	1.04 (± 1.62)	2.50 (± 2.47)	
Cycle 3 Day 1 (n=77, 65, 69)	1.72 (± 2.15)	0.90 (± 1.43)	1.49 (± 2.01)	
Cycle 3 Day 22 (n=74, 63, 63)	1.66 (± 2.07)	1.01 (± 1.58)	2.20 (± 2.42)	
Cycle 4 Day 1 (n=72, 61, 62)	1.59 (± 2.11)	1.24 (± 1.99)	1.61 (± 2.24)	
Cycle 4 Day 22 (n=68, 61, 59)	1.68 (± 2.31)	1.26 (± 1.98)	1.92 (± 2.00)	
Cycle 5 Day 1 (n=60, 52, 53)	1.70 (± 2.29)	0.69 (± 1.11)	1.53 (± 1.96)	
Cycle 5 Day 22 (n=60, 50, 47)	1.80 (± 2.29)	0.67 (± 1.33)	1.97 (± 2.21)	
Cycle 6 Day 1 (n=57, 47, 49)	1.91 (± 2.54)	0.64 (± 1.13)	1.39 (± 1.76)	
Cycle 6 Day 22 (n=56, 49, 44)	1.80 (± 2.38)	0.63 (± 1.12)	2.00 (± 2.23)	
Cycle 7 Day 1 (n=51, 41, 41)	1.99 (± 2.49)	0.53 (± 0.78)	1.00 (± 1.09)	
Cycle 7 Day 22 (n=51, 40, 38)	2.01 (± 2.45)	0.59 (± 0.93)	1.15 (± 1.04)	
Cycle 8 Day 1 (n=50, 41, 39)	1.88 (± 2.26)	0.55 (± 0.85)	0.94 (± 1.04)	
Cycle 8 Day 22 (n=51, 38, 36)	1.81 (± 2.41)	0.58 (± 0.91)	1.34 (± 1.39)	
Cycle 9 Day 1 (n=46, 34, 33)	1.75 (± 2.24)	0.55 (± 0.90)	1.16 (± 1.22)	
Cycle 9 Day 22 (n=46, 32, 28)	1.64 (± 2.16)	0.58 (± 0.89)	1.57 (± 1.61)	
Cycle 10 Day 1 (n=45, 33, 28)	1.43 (± 1.82)	0.81 (± 1.13)	1.08 (± 1.40)	
Cycle 10 Day 22 (n=43, 33, 29)	1.55 (± 2.09)	0.70 (± 1.10)	1.49 (± 1.78)	
Cycle 11 Day 1 (n=41, 30, 29)	1.65 (± 2.13)	0.61 (± 0.95)	0.98 (± 1.00)	
Cycle 11 Day 22 (n=38, 28, 26)	1.35 (± 1.81)	0.78 (± 1.07)	1.47 (± 1.61)	
Cycle 12 Day 1 (n=39, 28, 29)	1.21 (± 1.69)	0.68 (± 1.15)	0.84 (± 0.83)	
Cycle 12 Day 22 (n=38, 25, 26)	1.51 (± 2.23)	0.53 (± 0.99)	1.41 (± 1.53)	
Cycle 13 Day 1 (n=35, 23, 24)	1.50 (± 2.16)	0.68 (± 1.07)	1.26 (± 1.45)	
Cycle 13 Day 22 (n=37, 23, 20)	1.45 (± 2.32)	0.67 (± 1.10)	1.32 (± 1.37)	
Cycle 14 Day 1 (n=35, 21, 23)	1.60 (± 2.24)	0.67 (± 0.95)	1.07 (± 1.31)	
Cycle 14 Day 22 (n=35, 19, 20)	1.40 (± 2.09)	0.63 (± 0.94)	1.50 (± 1.48)	
Cycle 15 Day 1 (n=31, 17, 21)	1.16 (± 1.74)	0.84 (± 1.16)	1.50 (± 1.64)	
Cycle 15 Day 22 (n=28, 13, 15)	1.48 (± 1.92)	0.71 (± 1.10)	2.08 (± 1.64)	
Cycle 16 Day 1 (n=25, 13, 14)	0.87 (± 0.99)	0.85 (± 1.40)	1.07 (± 1.22)	
Cycle 16 Day 22 (n=23, 9, 14)	0.72 (± 0.93)	0.87 (± 1.30)	2.04 (± 2.24)	

Cycle 17 Day 1 (n=18, 10, 8)	0.98 (± 0.99)	0.57 (± 0.75)	0.71 (± 0.95)
Cycle 17 Day 22 (n=14, 8, 8)	0.73 (± 1.02)	0.65 (± 0.97)	1.21 (± 1.32)
Cycle 18 Day 1 (n=12, 8, 7)	0.93 (± 1.07)	0.71 (± 0.98)	0.95 (± 1.15)
Cycle 18 Day 22 (n=13, 6, 7)	0.79 (± 1.06)	0.33 (± 0.41)	1.05 (± 1.42)
Cycle 19 Day 1 (n=11, 6, 7)	1.11 (± 1.25)	0.31 (± 0.34)	1.33 (± 1.66)
Cycle 19 Day 22 (n=10, 5, 7)	0.97 (± 1.37)	0.30 (± 0.41)	1.55 (± 1.69)
Cycle 20 Day 1 (n=8, 4, 5)	1.19 (± 1.31)	0.21 (± 0.42)	0.90 (± 1.07)
Cycle 20 Day 22 (n=5, 4, 4)	1.10 (± 1.30)	0.04 (± 0.08)	1.67 (± 1.56)
Cycle 21 Day 1 (n=5, 2, 3)	1.17 (± 1.42)	0.00 (± 0.00)	0.78 (± 1.07)
Cycle 21 Day 22 (n=5, 1, 2)	1.23 (± 1.51)	0.00 (± 999999)	1.25 (± 1.53)
Cycle 22 Day 1 (n=4, 1, 2)	0.54 (± 0.76)	0.00 (± 999999)	0.83 (± 0.71)
Cycle 22 Day 22 (n=3, 1, 2)	0.94 (± 1.07)	0.00 (± 999999)	1.25 (± 1.53)
Cycle 23 Day 1 (n=2, 1, 2)	1.67 (± 1.89)	0.00 (± 999999)	1.58 (± 2.00)
Cycle 23 Day 22 (n=2, 1, 2)	1.25 (± 1.77)	0.00 (± 999999)	2.67 (± 2.36)
Cycle 24 Day 1 (n=1, 1, 1)	2.33 (± 999999)	0.00 (± 999999)	1.67 (± 999999)
Cycle 24 Day 22 (n=0, 1, 1)	999 (± 999)	0.00 (± 999999)	0.50 (± 999999)
Cycle 25 Day 1 (n=0, 1, 0)	999 (± 999)	0.00 (± 999999)	999 (± 999)
Treatment discontinuation (n=46, 39, 39)	2.54 (± 2.66)	2.29 (± 2.54)	3.49 (± 3.16)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Brief Fatigue Inventory (BFI) Fatigue Level Score

End point title	Brief Fatigue Inventory (BFI) Fatigue Level Score
End point description:	
BFI questionnaire comprises of 2 parts: fatigue level (3 items), interference with daily life (1 item with 6 sub-items). Each items in the fatigue level score was answered on a scale of 0 (no fatigue) to 10 (as bad as you can imagine). The mean score of all 3 items was reported on the scale of 0 (no fatigue) to 10 (as bad as you can imagine). PRO-evaluable population. 'Number of Subjects Analyzed'=participants evaluable for this outcome measure. 'n'=participants evaluable for this outcome measure at specified timepoint for each arm respectively. '999999' indicates that standard deviation was not estimable for single participant. '999' indicates that data were not estimable as there were no evaluable participants.	
End point type	Secondary
End point timeframe:	
Days 1 and 22 of Cycles 1 to 24; Day 1 of Cycle 25; treatment discontinuation (up to approximately 2.75 years) (1 cycle=6 weeks)	

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	95	94	93	
Units: units on a scale				
arithmetic mean (standard deviation)				
Cycle 1 Day 1 (n=93, 93, 92)	2.80 (± 2.64)	2.52 (± 2.72)	2.66 (± 2.74)	
Cycle 1 Day 22 (n=90, 86, 89)	3.80 (± 2.86)	2.55 (± 2.60)	4.42 (± 3.09)	
Cycle 2 Day 1 (n=86, 79, 79)	3.21 (± 2.61)	2.63 (± 2.69)	2.86 (± 2.76)	
Cycle 2 Day 22 (n=81, 82, 78)	3.15 (± 2.61)	2.57 (± 2.74)	3.69 (± 2.74)	
Cycle 3 Day 1 (n=76, 64, 69)	2.91 (± 2.60)	2.11 (± 2.42)	2.35 (± 2.44)	
Cycle 3 Day 22 (n=74, 62, 63)	2.93 (± 2.67)	2.31 (± 2.71)	3.60 (± 3.09)	
Cycle 4 Day 1 (n=72, 62, 62)	3.21 (± 2.66)	2.32 (± 2.86)	2.39 (± 2.47)	
Cycle 4 Day 22 (n=66, 61, 59)	3.06 (± 2.68)	2.33 (± 2.94)	3.15 (± 2.57)	
Cycle 5 Day 1 (n=59, 51, 53)	2.97 (± 2.83)	1.59 (± 2.03)	2.32 (± 2.62)	
Cycle 5 Day 22 (n=60, 50, 47)	3.02 (± 2.87)	1.34 (± 1.81)	2.91 (± 2.86)	
Cycle 6 Day 1 (n=57, 48, 49)	3.05 (± 2.83)	1.42 (± 1.90)	2.22 (± 2.48)	
Cycle 6 Day 22 (n=56, 49, 44)	3.23 (± 2.94)	1.39 (± 2.01)	3.09 (± 2.69)	
Cycle 7 Day 1 (n=51, 40, 40)	3.16 (± 2.81)	1.33 (± 1.91)	1.68 (± 1.75)	
Cycle 7 Day 22 (n=51, 41, 38)	2.86 (± 2.60)	1.24 (± 1.67)	2.16 (± 1.87)	
Cycle 8 Day 1 (n=50, 41, 39)	2.80 (± 2.56)	1.12 (± 1.68)	1.72 (± 1.70)	
Cycle 8 Day 22 (n=51, 38, 36)	2.88 (± 2.80)	1.24 (± 1.75)	2.58 (± 2.13)	
Cycle 9 Day 1 (n=46, 35, 34)	3.09 (± 2.81)	1.11 (± 1.55)	2.12 (± 2.48)	
Cycle 9 Day 22 (n=46, 32, 28)	2.80 (± 2.73)	1.19 (± 1.71)	2.64 (± 2.57)	
Cycle 10 Day 1 (n=45, 34, 28)	2.80 (± 2.58)	1.29 (± 1.88)	2.11 (± 2.23)	
Cycle 10 Day 22 (n=43, 33, 29)	2.91 (± 2.83)	1.33 (± 1.90)	2.24 (± 2.43)	
Cycle 11 Day 1 (n=40, 30, 28)	2.98 (± 2.71)	1.40 (± 1.96)	1.93 (± 1.65)	
Cycle 11 Day 22 (n=37, 29, 26)	2.59 (± 2.44)	1.72 (± 2.23)	2.42 (± 2.12)	
Cycle 12 Day 1 (n=39, 28, 29)	2.31 (± 2.25)	1.25 (± 1.96)	1.66 (± 1.67)	
Cycle 12 Day 22 (n=38, 25, 26)	2.79 (± 2.46)	1.44 (± 2.12)	2.27 (± 2.05)	
Cycle 13 Day 1 (n=36, 23, 24)	2.69 (± 2.57)	1.65 (± 2.17)	2.08 (± 1.56)	
Cycle 13 Day 22 (n=37, 22, 20)	2.97 (± 2.97)	1.55 (± 2.13)	2.60 (± 2.28)	
Cycle 14 Day 1 (n=35, 20, 23)	2.94 (± 2.94)	1.45 (± 2.14)	2.30 (± 2.34)	
Cycle 14 Day 22 (n=35, 18, 20)	2.83 (± 2.85)	1.61 (± 2.00)	2.60 (± 2.09)	
Cycle 15 Day 1 (n=30, 17, 20)	2.73 (± 2.56)	1.76 (± 2.19)	2.60 (± 2.33)	
Cycle 15 Day 22 (n=28, 13, 16)	2.61 (± 2.79)	0.92 (± 1.12)	2.94 (± 1.61)	
Cycle 16 Day 1 (n=25, 13, 14)	1.88 (± 1.99)	1.54 (± 2.07)	2.21 (± 2.42)	
Cycle 16 Day 22 (n=23, 9, 13)	1.70 (± 1.61)	2.11 (± 2.15)	2.85 (± 2.19)	
Cycle 17 Day 1 (n=18, 10, 8)	1.78 (± 1.59)	1.60 (± 1.96)	1.50 (± 1.51)	
Cycle 17 Day 22 (n=14, 8, 8)	2.00 (± 1.80)	2.13 (± 2.42)	2.38 (± 1.60)	
Cycle 18 Day 1 (n=13, 8, 7)	2.23 (± 1.74)	1.88 (± 2.23)	1.71 (± 1.70)	
Cycle 18 Day 22 (n=13, 6, 7)	1.92 (± 2.14)	1.67 (± 2.07)	2.14 (± 2.19)	
Cycle 19 Day 1 (n=12, 6, 7)	2.17 (± 2.48)	1.50 (± 1.97)	2.29 (± 3.30)	
Cycle 19 Day 22 (n=10, 5, 7)	1.90 (± 2.42)	1.40 (± 2.19)	3.29 (± 2.43)	
Cycle 20 Day 1 (n=8, 4, 5)	3.00 (± 3.16)	1.25 (± 2.50)	1.80 (± 1.30)	
Cycle 20 Day 22 (n=5, 4, 4)	2.40 (± 3.05)	1.50 (± 3.00)	2.25 (± 2.06)	
Cycle 21 Day 1 (n=5, 2, 3)	2.60 (± 2.97)	2.50 (± 3.54)	1.67 (± 1.53)	
Cycle 21 Day 22 (n=5, 1, 2)	2.40 (± 1.95)	0.00 (± 999999)	2.00 (± 1.41)	
Cycle 22 Day 1 (n=4, 1, 2)	1.25 (± 1.89)	0.00 (± 999999)	2.00 (± 1.41)	

Cycle 22 Day 22 (n=3, 1, 2)	1.33 (± 2.31)	0.00 (± 999999)	3.00 (± 2.83)	
Cycle 23 Day 1 (n=2, 1, 2)	2.50 (± 3.54)	0.00 (± 999999)	2.00 (± 2.83)	
Cycle 23 Day 22 (n=2, 1, 2)	2.00 (± 2.83)	0.00 (± 999999)	4.50 (± 3.54)	
Cycle 24 Day 1 (n=1, 1, 1)	4.00 (± 999999)	0.00 (± 999999)	2.00 (± 999999)	
Cycle 24 Day 22 (n=0, 1, 1)	999 (± 999)	0.00 (± 999999)	0.00 (± 999999)	
Cycle 25 Day 1 (n=0, 1, 0)	999 (± 999)	0.00 (± 999999)	999 (± 999)	
Treatment discontinuation (n=46, 39, 40)	3.74 (± 2.82)	3.95 (± 3.27)	3.75 (± 3.09)	

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: EuroQoL 5 Dimension (EQ-5D) Questionnaire Score

End point title	EuroQoL 5 Dimension (EQ-5D) Questionnaire Score
End point description:	
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state. Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.	
End point type	Other pre-specified
End point timeframe:	
Days 1 and 22 of Cycles 1 to 24; Day 1 of Cycle 25; treatment discontinuation (up to approximately 2.75 years) (1 cycle=6 weeks)	

End point values	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 <sup>[8]</sup>	0 <sup>[9]</sup>	0 <sup>[10]</sup>	
Units: units on a scale				
arithmetic mean (standard deviation)	( )	( )	( )	

Notes:

[8] - As this outcome was pre-specified as an exploratory outcome, no results are reported.

[9] - As this outcome was pre-specified as an exploratory outcome, no results are reported.

[10] - As this outcome was pre-specified as an exploratory outcome, no results are reported.

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Baseline up to approximately 60 months.

Adverse event reporting additional description:

Safety-evaluable population included all participants who received at least one dose of any study medication. Adverse events were reported separately for crossed over participants.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.1
--------------------	------

### Reporting groups

Reporting group title	Atezolizumab and Bevacizumab
-----------------------	------------------------------

Reporting group description:

Atezolizumab 1200 milligrams (mg) and bevacizumab 15 milligrams per kilogram (mg/kg) were administered as intravenous (IV) infusions every 3 weeks (q3w) on Day 1 and Day 22 of each 6-week cycle until disease progression.

Reporting group title	Atezolizumab
-----------------------	--------------

Reporting group description:

Atezolizumab 1200 mg was administered as IV infusion q3w on Day 1 and Day 22 of each 6-week cycle until disease progression. Upon disease progression, participants (except EU participants) could crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.

Reporting group title	Sunitinib
-----------------------	-----------

Reporting group description:

Sunitinib 50 mg was administered orally once daily on Days 1 to 28 of each 6-week cycle until disease progression. Upon disease progression, participants could crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.

Reporting group title	Atezolizumab (Crossover)
-----------------------	--------------------------

Reporting group description:

Among the participants assigned to atezolizumab initially, those participants who upon disease progression, crossed over to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination, were included in this group. Atezolizumab 1200 mg and bevacizumab 15 mg/kg were administered as IV infusions q3w on Day 1 and Day 22 of each 6-week cycle.

Reporting group title	Sunitinib (Crossover)
-----------------------	-----------------------

Reporting group description:

Among the participants assigned to sunitinib initially, those participants who upon disease progression, crossed over to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination, were included in this group. Atezolizumab 1200 mg and bevacizumab 15 mg/kg were administered as IV infusions q3w on Day 1 and Day 22 of each 6-week cycle.

Serious adverse events	Atezolizumab and Bevacizumab	Atezolizumab	Sunitinib
Total subjects affected by serious adverse events			
subjects affected / exposed	49 / 101 (48.51%)	37 / 103 (35.92%)	28 / 100 (28.00%)
number of deaths (all causes)	54	51	56
number of deaths resulting from adverse events			

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Intracranial tumour haemorrhage			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to central nervous system			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	4 / 101 (3.96%)	0 / 103 (0.00%)	2 / 100 (2.00%)
occurrences causally related to treatment / all	2 / 4	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			

subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Limb operation			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pain			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	2 / 101 (1.98%)	4 / 103 (3.88%)	2 / 100 (2.00%)
occurrences causally related to treatment / all	1 / 2	1 / 4	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Death			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Oedema			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthenia			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Haemophagocytic lymphohistiocytosis			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			

subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	1 / 101 (0.99%)	4 / 103 (3.88%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	1 / 101 (0.99%)	1 / 103 (0.97%)	2 / 100 (2.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal mass			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive airways disorder			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 101 (0.00%)	2 / 103 (1.94%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			

subjects affected / exposed	3 / 101 (2.97%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary haemorrhage			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatinine increased			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alanine aminotransferase increased			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase			

increased			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	0 / 101 (0.00%)	2 / 103 (1.94%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cardiac disorders			
Angina pectoris			
subjects affected / exposed	2 / 101 (1.98%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	1 / 101 (0.99%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiomyopathy			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	1 / 101 (0.99%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Amnesia			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune neuropathy			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Demyelination			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial paralysis			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	1 / 101 (0.99%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Headache			
subjects affected / exposed	2 / 101 (1.98%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiparesis			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nerve root compression			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral sensorimotor neuropathy			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			

subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial haematoma			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paresis			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Histiocytosis haematophagic			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			

Abdominal pain			
subjects affected / exposed	1 / 101 (0.99%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune pancreatitis			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	4 / 101 (3.96%)	0 / 103 (0.00%)	2 / 100 (2.00%)
occurrences causally related to treatment / all	3 / 5	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal inflammation			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease			

subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal haemorrhage			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Intestinal obstruction			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mesenteric vein thrombosis			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic fistula			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritoneal haemorrhage			

subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retroperitoneal haemorrhage			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 101 (0.99%)	1 / 103 (0.97%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis microscopic			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive pancreatitis			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Bile duct stenosis			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			

subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatorenal syndrome			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash erythematous			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash maculo–papular			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 101 (0.99%)	3 / 103 (2.91%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	1 / 1	2 / 4	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	3 / 101 (2.97%)	2 / 103 (1.94%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	2 / 3	0 / 2	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			

subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	2 / 100 (2.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urethral stenosis			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	2 / 100 (2.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chondrocalcinosis			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Flank pain			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture pain			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Muscle haemorrhage			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck pain			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathic arthropathy			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathological fracture			
subjects affected / exposed	2 / 101 (1.98%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis infective			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			

subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest wall abscess			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	3 / 101 (2.97%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	2 / 101 (1.98%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 101 (0.00%)	3 / 103 (2.91%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Meningitis viral			

subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Necrotising fasciitis</b>			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pancreatic abscess</b>			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Paronychia</b>			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Peritonitis bacterial</b>			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pneumonia</b>			
subjects affected / exposed	3 / 101 (2.97%)	2 / 103 (1.94%)	1 / 100 (1.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
<b>Sinusitis</b>			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Spinal cord infection</b>			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Staphylococcal infection</b>			

subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 101 (0.99%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary sepsis			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psoas abscess			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			

subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
Decreased appetite			
subjects affected / exposed	1 / 101 (0.99%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	2 / 101 (1.98%)	1 / 103 (0.97%)	2 / 100 (2.00%)
occurrences causally related to treatment / all	1 / 2	1 / 1	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus			
subjects affected / exposed	1 / 101 (0.99%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 101 (0.00%)	2 / 103 (1.94%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 101 (0.00%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	2 / 100 (2.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	4 / 101 (3.96%)	1 / 103 (0.97%)	0 / 100 (0.00%)
occurrences causally related to treatment / all	2 / 6	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Atezolizumab	Sunitinib	
-------------------------------	--------------	-----------	--

	(Crossover)	(Crossover)	
Total subjects affected by serious adverse events			
subjects affected / exposed	15 / 46 (32.61%)	22 / 63 (34.92%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Intracranial tumour haemorrhage			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to central nervous system			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolism			
subjects affected / exposed	1 / 46 (2.17%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			

subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	1 / 46 (2.17%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Limb operation			
subjects affected / exposed	1 / 46 (2.17%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			
subjects affected / exposed	1 / 46 (2.17%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mucosal inflammation			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Non–cardiac chest pain			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	0 / 46 (0.00%)	3 / 63 (4.76%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	0 / 46 (0.00%)	2 / 63 (3.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden death			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema			
subjects affected / exposed	1 / 46 (2.17%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthenia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Haemophagocytic lymphohistiocytosis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	1 / 46 (2.17%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal mass			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive airways disorder			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Pulmonary embolism			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary haemorrhage			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Blood creatinine increased			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alanine aminotransferase increased			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Aspartate aminotransferase increased			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood bilirubin increased			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incisional hernia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infusion related reaction			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	1 / 46 (2.17%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	1 / 46 (2.17%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiomyopathy			
subjects affected / exposed	1 / 46 (2.17%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Amnesia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autoimmune neuropathy			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Demyelination			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial paralysis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage intracranial			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nerve root compression			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral sensorimotor neuropathy			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord compression			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			

subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial haematoma			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paresis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Histiocytosis haematophagic			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			

Abdominal pain			
subjects affected / exposed	1 / 46 (2.17%)	2 / 63 (3.17%)	
occurrences causally related to treatment / all	3 / 3	3 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autoimmune pancreatitis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	1 / 46 (2.17%)	2 / 63 (3.17%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal inflammation			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophageal reflux disease			

subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal haemorrhage			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesenteric vein thrombosis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	0 / 46 (0.00%)	3 / 63 (4.76%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic fistula			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	1 / 46 (2.17%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritoneal haemorrhage			

subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal haemorrhage			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	0 / 46 (0.00%)	2 / 63 (3.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis microscopic			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive pancreatitis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Bile duct stenosis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			

subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatorenal syndrome			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperbilirubinaemia			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Rash erythematous			
subjects affected / exposed	1 / 46 (2.17%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash maculo-papular			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	2 / 46 (4.35%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			

subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral stenosis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	2 / 46 (4.35%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 46 (0.00%)	5 / 63 (7.94%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone pain			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chondrocalcinosis			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Flank pain			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fracture pain			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Muscle haemorrhage			
subjects affected / exposed	1 / 46 (2.17%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal pain			
subjects affected / exposed	1 / 46 (2.17%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain			
subjects affected / exposed	2 / 46 (4.35%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathic arthropathy			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	1 / 46 (2.17%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pathological fracture			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Appendicitis			
subjects affected / exposed	1 / 46 (2.17%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis infective			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			

subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	1 / 46 (2.17%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest wall abscess			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	1 / 46 (2.17%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis viral			

subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrotising fasciitis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic abscess			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paronychia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis bacterial			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinusitis			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord infection			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal infection			

subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary sepsis			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoas abscess			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	1 / 46 (2.17%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin infection			

subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	0 / 46 (0.00%)	3 / 63 (4.76%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	0 / 46 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	<b>Atezolizumab and Bevacizumab</b>	<b>Atezolizumab</b>	<b>Sunitinib</b>
Total subjects affected by non-serious adverse events			
subjects affected / exposed	99 / 101 (98.02%)	94 / 103 (91.26%)	99 / 100 (99.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	38 / 101 (37.62%)	10 / 103 (9.71%)	34 / 100 (34.00%)
occurrences (all)	62	18	52
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	7 / 101 (6.93%)	8 / 103 (7.77%)	7 / 100 (7.00%)
occurrences (all)	10	9	30
Chest pain			
subjects affected / exposed	7 / 101 (6.93%)	5 / 103 (4.85%)	6 / 100 (6.00%)
occurrences (all)	7	5	6
Chills			
subjects affected / exposed	5 / 101 (4.95%)	8 / 103 (7.77%)	13 / 100 (13.00%)
occurrences (all)	6	8	15
Fatigue			
subjects affected / exposed	62 / 101 (61.39%)	52 / 103 (50.49%)	70 / 100 (70.00%)
occurrences (all)	125	76	159
Influenza like illness			
subjects affected / exposed	8 / 101 (7.92%)	6 / 103 (5.83%)	3 / 100 (3.00%)
occurrences (all)	11	7	3
Mucosal inflammation			
subjects affected / exposed	18 / 101 (17.82%)	4 / 103 (3.88%)	33 / 100 (33.00%)
occurrences (all)	30	5	67
Oedema peripheral			
subjects affected / exposed	20 / 101 (19.80%)	12 / 103 (11.65%)	10 / 100 (10.00%)
occurrences (all)	28	14	12

Pain			
subjects affected / exposed	16 / 101 (15.84%)	7 / 103 (6.80%)	10 / 100 (10.00%)
occurrences (all)	20	8	12
Pyrexia			
subjects affected / exposed	19 / 101 (18.81%)	23 / 103 (22.33%)	10 / 100 (10.00%)
occurrences (all)	23	25	13
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	24 / 101 (23.76%)	26 / 103 (25.24%)	25 / 100 (25.00%)
occurrences (all)	33	48	31
Dysphonia			
subjects affected / exposed	18 / 101 (17.82%)	2 / 103 (1.94%)	4 / 100 (4.00%)
occurrences (all)	19	2	4
Dyspnoea			
subjects affected / exposed	19 / 101 (18.81%)	18 / 103 (17.48%)	18 / 100 (18.00%)
occurrences (all)	31	20	30
Dyspnoea exertional			
subjects affected / exposed	5 / 101 (4.95%)	7 / 103 (6.80%)	8 / 100 (8.00%)
occurrences (all)	5	8	10
Epistaxis			
subjects affected / exposed	29 / 101 (28.71%)	2 / 103 (1.94%)	12 / 100 (12.00%)
occurrences (all)	37	4	17
Nasal congestion			
subjects affected / exposed	12 / 101 (11.88%)	11 / 103 (10.68%)	3 / 100 (3.00%)
occurrences (all)	18	15	3
Oropharyngeal pain			
subjects affected / exposed	12 / 101 (11.88%)	11 / 103 (10.68%)	3 / 100 (3.00%)
occurrences (all)	14	14	4
Productive cough			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	6 / 101 (5.94%)	6 / 103 (5.83%)	3 / 100 (3.00%)
occurrences (all)	6	8	3
Sinus Congestion			

subjects affected / exposed occurrences (all)	7 / 101 (6.93%) 7	2 / 103 (1.94%) 2	2 / 100 (2.00%) 2
Psychiatric disorders			
Anxiety			
subjects affected / exposed	8 / 101 (7.92%)	6 / 103 (5.83%)	6 / 100 (6.00%)
occurrences (all)	10	6	7
Depression			
subjects affected / exposed	9 / 101 (8.91%)	5 / 103 (4.85%)	7 / 100 (7.00%)
occurrences (all)	11	5	12
Insomnia			
subjects affected / exposed	10 / 101 (9.90%)	7 / 103 (6.80%)	12 / 100 (12.00%)
occurrences (all)	11	8	14
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	14 / 101 (13.86%)	7 / 103 (6.80%)	15 / 100 (15.00%)
occurrences (all)	25	12	23
Aspartate aminotransferase increased			
subjects affected / exposed	10 / 101 (9.90%)	7 / 103 (6.80%)	17 / 100 (17.00%)
occurrences (all)	14	14	27
Blood alkaline phosphatase increased			
subjects affected / exposed	8 / 101 (7.92%)	3 / 103 (2.91%)	6 / 100 (6.00%)
occurrences (all)	14	4	9
Blood creatinine increased			
subjects affected / exposed	13 / 101 (12.87%)	17 / 103 (16.50%)	14 / 100 (14.00%)
occurrences (all)	21	29	29
Platelet count decreased			
subjects affected / exposed	2 / 101 (1.98%)	2 / 103 (1.94%)	6 / 100 (6.00%)
occurrences (all)	2	4	11
Weight decreased			
subjects affected / exposed	18 / 101 (17.82%)	5 / 103 (4.85%)	10 / 100 (10.00%)
occurrences (all)	23	6	13
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences (all)	0	0	0
Protein total increased			

subjects affected / exposed occurrences (all)	0 / 101 (0.00%) 0	0 / 103 (0.00%) 0	0 / 100 (0.00%) 0
Injury, poisoning and procedural complications Contusion subjects affected / exposed occurrences (all)	0 / 101 (0.00%) 0	0 / 103 (0.00%) 0	0 / 100 (0.00%) 0
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	13 / 101 (12.87%) 16	9 / 103 (8.74%) 13	13 / 100 (13.00%) 18
Dysgeusia subjects affected / exposed occurrences (all)	12 / 101 (11.88%) 14	3 / 103 (2.91%) 4	30 / 100 (30.00%) 51
Headache subjects affected / exposed occurrences (all)	35 / 101 (34.65%) 70	16 / 103 (15.53%) 24	23 / 100 (23.00%) 40
Neuropathy peripheral subjects affected / exposed occurrences (all)	5 / 101 (4.95%) 5	1 / 103 (0.97%) 1	5 / 100 (5.00%) 5
Paraesthesia subjects affected / exposed occurrences (all)	8 / 101 (7.92%) 10	8 / 103 (7.77%) 8	11 / 100 (11.00%) 13
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	11 / 101 (10.89%) 21	19 / 103 (18.45%) 31	18 / 100 (18.00%) 29
Leukopenia subjects affected / exposed occurrences (all)	0 / 101 (0.00%) 0	0 / 103 (0.00%) 0	9 / 100 (9.00%) 38
Neutropenia subjects affected / exposed occurrences (all)	2 / 101 (1.98%) 5	1 / 103 (0.97%) 1	12 / 100 (12.00%) 51
Thrombocytopenia subjects affected / exposed occurrences (all)	6 / 101 (5.94%) 12	1 / 103 (0.97%) 1	15 / 100 (15.00%) 30
Eye disorders			

Dry eye			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	8 / 101 (7.92%)	2 / 103 (1.94%)	3 / 100 (3.00%)
occurrences (all)	8	2	6
Abdominal pain			
subjects affected / exposed	17 / 101 (16.83%)	8 / 103 (7.77%)	16 / 100 (16.00%)
occurrences (all)	22	9	18
Abdominal pain upper			
subjects affected / exposed	4 / 101 (3.96%)	2 / 103 (1.94%)	9 / 100 (9.00%)
occurrences (all)	4	2	10
Constipation			
subjects affected / exposed	30 / 101 (29.70%)	16 / 103 (15.53%)	30 / 100 (30.00%)
occurrences (all)	45	19	37
Diarrhoea			
subjects affected / exposed	36 / 101 (35.64%)	20 / 103 (19.42%)	62 / 100 (62.00%)
occurrences (all)	67	28	180
Dry mouth			
subjects affected / exposed	12 / 101 (11.88%)	12 / 103 (11.65%)	9 / 100 (9.00%)
occurrences (all)	13	12	11
Dyspepsia			
subjects affected / exposed	8 / 101 (7.92%)	4 / 103 (3.88%)	20 / 100 (20.00%)
occurrences (all)	11	7	30
Gastrooesophageal reflux disease			
subjects affected / exposed	7 / 101 (6.93%)	3 / 103 (2.91%)	13 / 100 (13.00%)
occurrences (all)	8	4	16
Gingival bleeding			
subjects affected / exposed	7 / 101 (6.93%)	0 / 103 (0.00%)	1 / 100 (1.00%)
occurrences (all)	8	0	5
Nausea			
subjects affected / exposed	40 / 101 (39.60%)	19 / 103 (18.45%)	46 / 100 (46.00%)
occurrences (all)	61	30	87
Oral pain			

subjects affected / exposed	4 / 101 (3.96%)	0 / 103 (0.00%)	7 / 100 (7.00%)
occurrences (all)	7	0	8
Stomatitis			
subjects affected / exposed	15 / 101 (14.85%)	3 / 103 (2.91%)	25 / 100 (25.00%)
occurrences (all)	20	4	50
Vomiting			
subjects affected / exposed	20 / 101 (19.80%)	8 / 103 (7.77%)	21 / 100 (21.00%)
occurrences (all)	25	14	30
Skin and subcutaneous tissue disorders			
Dry skin			
subjects affected / exposed	13 / 101 (12.87%)	15 / 103 (14.56%)	10 / 100 (10.00%)
occurrences (all)	18	16	15
Night sweats			
subjects affected / exposed	8 / 101 (7.92%)	5 / 103 (4.85%)	7 / 100 (7.00%)
occurrences (all)	10	6	7
Palmar–plantar erythrodysaesthesia syndrome			
subjects affected / exposed	3 / 101 (2.97%)	0 / 103 (0.00%)	41 / 100 (41.00%)
occurrences (all)	12	0	133
Pruritus			
subjects affected / exposed	27 / 101 (26.73%)	18 / 103 (17.48%)	10 / 100 (10.00%)
occurrences (all)	40	40	15
Rash			
subjects affected / exposed	28 / 101 (27.72%)	24 / 103 (23.30%)	14 / 100 (14.00%)
occurrences (all)	48	38	22
Ecchymosis			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences (all)	0	0	0
Rash erythematous			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			

Dysuria			
subjects affected / exposed	1 / 101 (0.99%)	7 / 103 (6.80%)	2 / 100 (2.00%)
occurrences (all)	1	7	2
Haematuria			
subjects affected / exposed	3 / 101 (2.97%)	10 / 103 (9.71%)	9 / 100 (9.00%)
occurrences (all)	4	18	9
Proteinuria			
subjects affected / exposed	38 / 101 (37.62%)	10 / 103 (9.71%)	9 / 100 (9.00%)
occurrences (all)	89	17	10
Acute kidney injury			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences (all)	0	0	0
Nocturia			
subjects affected / exposed	6 / 101 (5.94%)	2 / 103 (1.94%)	4 / 100 (4.00%)
occurrences (all)	6	2	4
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	19 / 101 (18.81%)	12 / 103 (11.65%)	20 / 100 (20.00%)
occurrences (all)	19	15	21
Adrenal insufficiency			
subjects affected / exposed	0 / 101 (0.00%)	0 / 103 (0.00%)	0 / 100 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	40 / 101 (39.60%)	19 / 103 (18.45%)	19 / 100 (19.00%)
occurrences (all)	73	34	24
Back pain			
subjects affected / exposed	19 / 101 (18.81%)	18 / 103 (17.48%)	20 / 100 (20.00%)
occurrences (all)	22	24	28
Muscle spasms			
subjects affected / exposed	8 / 101 (7.92%)	2 / 103 (1.94%)	6 / 100 (6.00%)
occurrences (all)	8	2	7
Musculoskeletal pain			
subjects affected / exposed	22 / 101 (21.78%)	10 / 103 (9.71%)	6 / 100 (6.00%)
occurrences (all)	29	13	7
Myalgia			

subjects affected / exposed occurrences (all)	12 / 101 (11.88%) 16	10 / 103 (9.71%) 14	15 / 100 (15.00%) 15
Neck pain subjects affected / exposed occurrences (all)	10 / 101 (9.90%) 11	5 / 103 (4.85%) 5	8 / 100 (8.00%) 8
Pain in extremity subjects affected / exposed occurrences (all)	17 / 101 (16.83%) 25	8 / 103 (7.77%) 12	17 / 100 (17.00%) 24
Flank pain subjects affected / exposed occurrences (all)	0 / 101 (0.00%) 0	0 / 103 (0.00%) 0	0 / 100 (0.00%) 0
<b>Infections and infestations</b>			
Nasopharyngitis subjects affected / exposed occurrences (all)	11 / 101 (10.89%) 13	8 / 103 (7.77%) 11	2 / 100 (2.00%) 2
Rhinitis subjects affected / exposed occurrences (all)	8 / 101 (7.92%) 8	6 / 103 (5.83%) 6	1 / 100 (1.00%) 1
Sinusitis subjects affected / exposed occurrences (all)	15 / 101 (14.85%) 22	5 / 103 (4.85%) 6	3 / 100 (3.00%) 4
Upper respiratory tract infection subjects affected / exposed occurrences (all)	14 / 101 (13.86%) 16	11 / 103 (10.68%) 16	5 / 100 (5.00%) 6
Urinary tract infection subjects affected / exposed occurrences (all)	10 / 101 (9.90%) 12	8 / 103 (7.77%) 31	3 / 100 (3.00%) 3
Pneumonia subjects affected / exposed occurrences (all)	0 / 101 (0.00%) 0	0 / 103 (0.00%) 0	0 / 100 (0.00%) 0
<b>Metabolism and nutrition disorders</b>			
Decreased appetite subjects affected / exposed occurrences (all)	23 / 101 (22.77%) 32	11 / 103 (10.68%) 15	30 / 100 (30.00%) 54
Dehydration			

subjects affected / exposed	11 / 101 (10.89%)	5 / 103 (4.85%)	4 / 100 (4.00%)
occurrences (all)	12	10	8
Hypercalcaemia			
subjects affected / exposed	10 / 101 (9.90%)	4 / 103 (3.88%)	4 / 100 (4.00%)
occurrences (all)	20	4	6
Hyperglycaemia			
subjects affected / exposed	8 / 101 (7.92%)	13 / 103 (12.62%)	5 / 100 (5.00%)
occurrences (all)	14	30	6
Hyperkalaemia			
subjects affected / exposed	15 / 101 (14.85%)	6 / 103 (5.83%)	6 / 100 (6.00%)
occurrences (all)	22	15	9
Hypoalbuminaemia			
subjects affected / exposed	6 / 101 (5.94%)	2 / 103 (1.94%)	5 / 100 (5.00%)
occurrences (all)	16	5	7
Hypomagnesaemia			
subjects affected / exposed	10 / 101 (9.90%)	2 / 103 (1.94%)	6 / 100 (6.00%)
occurrences (all)	19	2	8
Hyponatraemia			
subjects affected / exposed	12 / 101 (11.88%)	5 / 103 (4.85%)	7 / 100 (7.00%)
occurrences (all)	34	5	10
Hypophosphataemia			
subjects affected / exposed	6 / 101 (5.94%)	11 / 103 (10.68%)	11 / 100 (11.00%)
occurrences (all)	10	45	22

<b>Non-serious adverse events</b>	Atezolizumab (Crossover)	Sunitinib (Crossover)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	44 / 46 (95.65%)	57 / 63 (90.48%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	3 / 46 (6.52%)	0 / 63 (0.00%)	
occurrences (all)	3	0	
Vascular disorders			
Hypertension			
subjects affected / exposed	12 / 46 (26.09%)	13 / 63 (20.63%)	
occurrences (all)	15	26	
General disorders and administration site conditions			

Asthenia			
subjects affected / exposed	1 / 46 (2.17%)	7 / 63 (11.11%)	
occurrences (all)	1	11	
Chest pain			
subjects affected / exposed	4 / 46 (8.70%)	1 / 63 (1.59%)	
occurrences (all)	5	1	
Chills			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Fatigue			
subjects affected / exposed	19 / 46 (41.30%)	27 / 63 (42.86%)	
occurrences (all)	40	44	
Influenza like illness			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Mucosal inflammation			
subjects affected / exposed	6 / 46 (13.04%)	4 / 63 (6.35%)	
occurrences (all)	13	8	
Oedema peripheral			
subjects affected / exposed	8 / 46 (17.39%)	10 / 63 (15.87%)	
occurrences (all)	17	12	
Pain			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Pyrexia			
subjects affected / exposed	6 / 46 (13.04%)	10 / 63 (15.87%)	
occurrences (all)	7	15	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	14 / 46 (30.43%)	12 / 63 (19.05%)	
occurrences (all)	19	21	
Dysphonia			
subjects affected / exposed	9 / 46 (19.57%)	8 / 63 (12.70%)	
occurrences (all)	9	10	
Dyspnoea			

subjects affected / exposed	8 / 46 (17.39%)	10 / 63 (15.87%)	
occurrences (all)	11	11	
Dyspnoea exertional			
subjects affected / exposed	3 / 46 (6.52%)	2 / 63 (3.17%)	
occurrences (all)	4	2	
Epistaxis			
subjects affected / exposed	13 / 46 (28.26%)	5 / 63 (7.94%)	
occurrences (all)	17	6	
Nasal congestion			
subjects affected / exposed	5 / 46 (10.87%)	4 / 63 (6.35%)	
occurrences (all)	8	4	
Oropharyngeal pain			
subjects affected / exposed	6 / 46 (13.04%)	0 / 63 (0.00%)	
occurrences (all)	6	0	
Productive cough			
subjects affected / exposed	5 / 46 (10.87%)	2 / 63 (3.17%)	
occurrences (all)	8	3	
Rhinorrhoea			
subjects affected / exposed	3 / 46 (6.52%)	1 / 63 (1.59%)	
occurrences (all)	3	3	
Sinus Congestion			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 46 (2.17%)	6 / 63 (9.52%)	
occurrences (all)	1	6	
Depression			
subjects affected / exposed	2 / 46 (4.35%)	4 / 63 (6.35%)	
occurrences (all)	3	4	
Insomnia			
subjects affected / exposed	3 / 46 (6.52%)	8 / 63 (12.70%)	
occurrences (all)	3	8	
Investigations			
Alanine aminotransferase increased			

subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Blood creatinine increased			
subjects affected / exposed	10 / 46 (21.74%)	8 / 63 (12.70%)	
occurrences (all)	21	16	
Platelet count decreased			
subjects affected / exposed	3 / 46 (6.52%)	0 / 63 (0.00%)	
occurrences (all)	7	0	
Weight decreased			
subjects affected / exposed	2 / 46 (4.35%)	6 / 63 (9.52%)	
occurrences (all)	2	6	
Blood lactate dehydrogenase increased			
subjects affected / exposed	3 / 46 (6.52%)	3 / 63 (4.76%)	
occurrences (all)	4	8	
Protein total increased			
subjects affected / exposed	3 / 46 (6.52%)	1 / 63 (1.59%)	
occurrences (all)	8	3	
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	3 / 46 (6.52%)	2 / 63 (3.17%)	
occurrences (all)	3	2	
Nervous system disorders			
Dizziness			
subjects affected / exposed	4 / 46 (8.70%)	6 / 63 (9.52%)	
occurrences (all)	4	7	
Dysgeusia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Headache			

subjects affected / exposed	7 / 46 (15.22%)	13 / 63 (20.63%)	
occurrences (all)	10	19	
Neuropathy peripheral			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Paraesthesia			
subjects affected / exposed	1 / 46 (2.17%)	4 / 63 (6.35%)	
occurrences (all)	1	5	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 46 (4.35%)	9 / 63 (14.29%)	
occurrences (all)	5	11	
Leukopenia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Neutropenia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Thrombocytopenia			
subjects affected / exposed	2 / 46 (4.35%)	4 / 63 (6.35%)	
occurrences (all)	2	8	
Eye disorders			
Dry eye			
subjects affected / exposed	3 / 46 (6.52%)	0 / 63 (0.00%)	
occurrences (all)	3	0	
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Abdominal pain			
subjects affected / exposed	5 / 46 (10.87%)	7 / 63 (11.11%)	
occurrences (all)	6	9	
Abdominal pain upper			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Constipation			

subjects affected / exposed	10 / 46 (21.74%)	15 / 63 (23.81%)	
occurrences (all)	17	30	
Diarrhoea			
subjects affected / exposed	13 / 46 (28.26%)	19 / 63 (30.16%)	
occurrences (all)	30	46	
Dry mouth			
subjects affected / exposed	5 / 46 (10.87%)	5 / 63 (7.94%)	
occurrences (all)	6	5	
Dyspepsia			
subjects affected / exposed	3 / 46 (6.52%)	4 / 63 (6.35%)	
occurrences (all)	3	4	
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Gingival bleeding			
subjects affected / exposed	3 / 46 (6.52%)	2 / 63 (3.17%)	
occurrences (all)	3	3	
Nausea			
subjects affected / exposed	14 / 46 (30.43%)	21 / 63 (33.33%)	
occurrences (all)	20	31	
Oral pain			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Stomatitis			
subjects affected / exposed	14 / 46 (30.43%)	21 / 63 (33.33%)	
occurrences (all)	20	31	
Vomiting			
subjects affected / exposed	6 / 46 (13.04%)	16 / 63 (25.40%)	
occurrences (all)	8	27	
Skin and subcutaneous tissue disorders			
Dry skin			
subjects affected / exposed	5 / 46 (10.87%)	2 / 63 (3.17%)	
occurrences (all)	8	4	
Night sweats			
subjects affected / exposed	4 / 46 (8.70%)	3 / 63 (4.76%)	
occurrences (all)	5	4	

Palmar–plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Pruritus			
subjects affected / exposed	8 / 46 (17.39%)	7 / 63 (11.11%)	
occurrences (all)	16	12	
Rash			
subjects affected / exposed	12 / 46 (26.09%)	7 / 63 (11.11%)	
occurrences (all)	23	14	
Ecchymosis			
subjects affected / exposed	3 / 46 (6.52%)	0 / 63 (0.00%)	
occurrences (all)	3	0	
Hyperhidrosis			
subjects affected / exposed	0 / 46 (0.00%)	4 / 63 (6.35%)	
occurrences (all)	0	4	
Rash erythematous			
subjects affected / exposed	3 / 46 (6.52%)	1 / 63 (1.59%)	
occurrences (all)	4	1	
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Haematuria			
subjects affected / exposed	4 / 46 (8.70%)	4 / 63 (6.35%)	
occurrences (all)	7	11	
Proteinuria			
subjects affected / exposed	21 / 46 (45.65%)	25 / 63 (39.68%)	
occurrences (all)	64	55	
Acute kidney injury			
subjects affected / exposed	3 / 46 (6.52%)	2 / 63 (3.17%)	
occurrences (all)	3	2	
Nocturia			
subjects affected / exposed	3 / 46 (6.52%)	1 / 63 (1.59%)	
occurrences (all)	3	1	
Endocrine disorders			

Hypothyroidism subjects affected / exposed occurrences (all)	8 / 46 (17.39%) 9	7 / 63 (11.11%) 9	
Adrenal insufficiency subjects affected / exposed occurrences (all)	3 / 46 (6.52%) 3	0 / 63 (0.00%) 0	
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	17 / 46 (36.96%) 22	15 / 63 (23.81%) 25	
Back pain subjects affected / exposed occurrences (all)	8 / 46 (17.39%) 9	11 / 63 (17.46%) 12	
Muscle spasms subjects affected / exposed occurrences (all)	4 / 46 (8.70%) 4	1 / 63 (1.59%) 1	
Musculoskeletal pain subjects affected / exposed occurrences (all)	9 / 46 (19.57%) 11	5 / 63 (7.94%) 7	
Myalgia subjects affected / exposed occurrences (all)	3 / 46 (6.52%) 3	7 / 63 (11.11%) 9	
Neck pain subjects affected / exposed occurrences (all)	3 / 46 (6.52%) 3	1 / 63 (1.59%) 1	
Pain in extremity subjects affected / exposed occurrences (all)	9 / 46 (19.57%) 12	6 / 63 (9.52%) 9	
Flank pain subjects affected / exposed occurrences (all)	3 / 46 (6.52%) 3	2 / 63 (3.17%) 2	
Infections and infestations			
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 46 (0.00%) 0	0 / 63 (0.00%) 0	
Rhinitis			

subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Sinusitis			
subjects affected / exposed	4 / 46 (8.70%)	4 / 63 (6.35%)	
occurrences (all)	5	4	
Upper respiratory tract infection			
subjects affected / exposed	8 / 46 (17.39%)	2 / 63 (3.17%)	
occurrences (all)	12	2	
Urinary tract infection			
subjects affected / exposed	1 / 46 (2.17%)	4 / 63 (6.35%)	
occurrences (all)	1	4	
Pneumonia			
subjects affected / exposed	3 / 46 (6.52%)	1 / 63 (1.59%)	
occurrences (all)	3	1	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	4 / 46 (8.70%)	15 / 63 (23.81%)	
occurrences (all)	7	18	
Dehydration			
subjects affected / exposed	3 / 46 (6.52%)	6 / 63 (9.52%)	
occurrences (all)	3	7	
Hypercalcaemia			
subjects affected / exposed	0 / 46 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Hyperglycaemia			
subjects affected / exposed	5 / 46 (10.87%)	5 / 63 (7.94%)	
occurrences (all)	15	11	
Hyperkalaemia			
subjects affected / exposed	4 / 46 (8.70%)	4 / 63 (6.35%)	
occurrences (all)	8	7	
Hypoalbuminaemia			
subjects affected / exposed	3 / 46 (6.52%)	4 / 63 (6.35%)	
occurrences (all)	3	5	
Hypomagnesaemia			
subjects affected / exposed	2 / 46 (4.35%)	4 / 63 (6.35%)	
occurrences (all)	2	9	

Hyponatraemia			
subjects affected / exposed	5 / 46 (10.87%)	10 / 63 (15.87%)	
occurrences (all)	9	26	
Hypophosphataemia			
subjects affected / exposed	4 / 46 (8.70%)	4 / 63 (6.35%)	
occurrences (all)	10	6	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
23 October 2013	Protocol was amended primarily to allow investigators to use an alternate atezolizumab drug formulation (a Phase 3 formulation). In addition, further rationale for conducting fresh tumor biopsy was listed.
25 February 2014	Protocol was amended in response to the Voluntary Harmonisation Procedure (VHP), and the major clarifications were as follows: The term "immune related" as it pertains to tumor assessments was clarified and the term "modified RECIST" was used instead; Participants in Europe, including in France, Italy, the United Kingdom, Romania, Spain, Germany, Ukraine, the Czech Republic, and Poland, who were enrolled in atezolizumab monotherapy arm were not be allowed to cross over to combination therapy arm following disease progression; The exclusion criterion for participants with a positive human immunodeficiency virus (HIV) test was updated; The timing of vital signs measurements for participants in atezolizumab monotherapy was clarified.
21 August 2014	Protocol was amended to allow enrollment of approximately 300 participants (~100 participants in each treatment arm) in order to obtain the same level of precision in estimating the treatment effect for this subpopulation. Eligible renal cell carcinoma participants were to be enrolled regardless of IHC status; participants were randomized in one of three treatment arms, stratified in part by PD-L1 status. The study objective text was updated to reflect IHC 1/2/3. PFS and other efficacy endpoints were to be evaluated in the ITT population as well as in renal cell carcinoma participants with IHC 1/2/3 status.
31 October 2014	The protocol was amended, as requested by European health authority via VHP, to change the window for pregnancy testing from 28 days prior to Cycle 1, Day 1 to 7 days prior to Cycle 1, Day 1.
06 February 2015	The protocol was primarily amended to clarify the frequency of tumor assessments and to revise the tumor assessment schedule for participants who had treatment delays or interruptions.
28 October 2015	As per the more defined guidelines for the management of immune-mediated toxicity outlined in the updated atezolizumab Investigator's Brochure, management of gastrointestinal, dermatologic, endocrine, pulmonary toxicity, hepatotoxicity, potential pancreatic or eye toxicity and other immune-mediated adverse events was updated; The use of any live vaccine was updated to be prohibited within 90 days following administration of last dose of study drug in addition to 4 weeks prior and during study treatment; Systemic immune activation (SIA) was identified as a potential risk of atezolizumab when given in combination with other immunomodulating agents; Clarification of childbearing potential was added; Acceptable non-hormonal contraceptive methods were added; Bevacizumab dosing was clarified with 15 mg/kg administered every 3 weeks on Days 1 and 22 of each 6-week cycle; Participants who crossed over to treatment with atezolizumab and bevacizumab combination should have a new baseline tumor assessment within 28 days prior to crossover Cycle 1, Day 1; A revised blood and serum biomarker sampling schedule was provided; The reportable non-serious adverse effects of special interest (AESI) were updated.
21 January 2016	Protocol was amended to incorporate multi-European Competent Authorities recommendation following assessment through the VHP as follows: The list of non-hormonal contraceptive methods was removed because these methods were not considered highly effective when used alone.
30 July 2016	This protocol amendment reflected changes to the primary and secondary endpoints and the analysis plan of the study. Clinical data supporting these changes were added.

---

Notes:

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported